1
|
Minhas AMK, Sedhom R, Jean ED, Shapiro MD, Panza JA, Alam M, Virani SS, Ballantyne CM, Abramov D. Global burden of cardiovascular disease attributable to smoking, 1990-2019: an analysis of the 2019 Global Burden of Disease Study. Eur J Prev Cardiol 2024:zwae040. [PMID: 38589018 DOI: 10.1093/eurjpc/zwae040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 01/16/2024] [Accepted: 01/28/2024] [Indexed: 04/10/2024]
Abstract
AIMS This study aims to investigate the trends in the global cardiovascular disease (CVD) burden attributable to smoking from 1990 to 2019. METHODS AND RESULTS Global Burden of Disease Study 2019 was used to analyse the burden of CVD attributable to smoking (i.e. ischaemic heart disease, peripheral artery disease, stroke, atrial fibrillation and flutter, and aortic aneurysm). Age-standardized mortality rates (ASMRs) per 100 000 and age-standardized disability-adjusted life year rates (ASDRs) per 100 000, as well as an estimated annual percentage change (EAPC) in ASMR and ASDR, were determined by age, sex, year, socio-demographic index (SDI), regions, and countries or territories. The global ASMR of smoking-attributed CVD decreased from 57.16/100 000 [95% uncertainty interval (UI) 54.46-59.97] in 1990 to 33.03/100 000 (95% UI 30.43-35.51) in 2019 [EAPC -0.42 (95% UI -0.47 to -0.38)]. Similarly, the ASDR of smoking-attributed CVD decreased between 1990 and 2019. All CVD subcategories showed a decline in death burden between 1990 and 2019. The burden of smoking-attributed CVD was higher in men than in women. Significant geographic and regional variations existed such that Eastern Europe had the highest ASMR and Andean Latin America had the lowest ASMR in 2019. In 2019, the ASMR of smoking-attributed CVD was lowest in high SDI regions. CONCLUSION Smoking-attributed CVD morbidity and mortality are declining globally, but significant variation persists, indicating a need for targeted interventions to reduce smoking-related CVD burden.
Collapse
Affiliation(s)
| | - Ramy Sedhom
- Division of Cardiology, Loma Linda University Medical Center, Loma Linda, 2068 Orange Tree Lane, Suite 215, Redlands, CA 92374, USA
| | - Estelle D Jean
- Department of Cardiology, Medstar Heart and Vascular Institute, Silver Springs, MD, USA
| | - Michael D Shapiro
- Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA
| | - Julio A Panza
- Department of Cardiology, Westchester Medical Center, Valhalla, NY, USA
| | - Mahboob Alam
- Section of Cardiology, Baylor College of Medicine, Houston, TX, USA
| | - Salim S Virani
- Aga Khan University, Karachi, Pakistan
- Baylor College of Medicine and Texas Heart Institute, Houston, TX, USA
| | | | - Dmitry Abramov
- Division of Cardiology, Loma Linda University Medical Center, Loma Linda, 2068 Orange Tree Lane, Suite 215, Redlands, CA 92374, USA
| |
Collapse
|
2
|
Sreenivasan J, Malik A, Khan MS, Lloji A, Hooda U, Aronow WS, Lanier GM, Pan S, Greene SJ, Murad MH, Michos ED, Cooper HA, Gass A, Gupta R, Desai NR, Mentz RJ, Frishman WH, Panza JA. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis. Cardiol Rev 2024; 32:114-123. [PMID: 36576372 DOI: 10.1097/crd.0000000000000484] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Various pharmacotherapies exist for heart failure with preserved ejection fraction (HFpEF), but with unclear comparative efficacy. We searched EMBASE, Medline, and Cochrane Library from inception through August 2021 for all randomized clinical trials in HFpEF (EF >40%) that evaluated beta-blockers, mineralocorticoid receptor antagonist (MRA), angiotensin-converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Outcomes assessed were cardiovascular mortality, all-cause mortality, and HF hospitalization. A frequentist network meta-analysis was performed with a random-effects model. We included 22 randomized clinical trials (30,673 participants; mean age = 71.7 ± 4.2 years; females = 49.3 ± 7.7%; median follow-up = 24.4 ± 11.1 months). Compared with placebo, there was no statistically significant difference in cardiovascular mortality [beta-blockers; odds ratio (OR) 0.79 (0.46-1.34), MRA; OR 0.90 (0.70-1.14), ACE OR 0.95 (0.59-1.53), ARB; OR 1.02 (0.87-1.19), ARNI; OR 0.97 (0.74-1.26) and SGLT2i; OR 1.00 (0.84-1.18)] or all-cause mortality [beta blockers; OR 0.75 (0.54-1.04), MRA; OR 0.90 (0.75-1.08) ACE; OR 1.05 (0.71-1.54), ARB; OR 1.03 (0.91-1.15), ARNI; OR 0.99 (0.82-1.20) and SGLT2i; OR 1.00 (0.89-1.13)]. The certainty in these estimates was low or very low. There was a significantly reduction in HF hospitalization with the use of SGLT2i [OR 0.71 (0.62-0.82), moderate certainty], ARNI [OR 0.77 (0.63-0.94), low certainty], and MRA [OR 0.81 (0.66-0.98), moderate certainty]; with corresponding P scores of 0.84, 0.68, and 0.58, respectively. In HFpEF, the use of beta-blockers, MRA, ACE/ARB/ARNI, or SGLT2i was not associated with improved cardiovascular or all-cause mortality. SGLT2i, ARNI, and MRA reduced the risk of HF hospitalizations.
Collapse
Affiliation(s)
- Jayakumar Sreenivasan
- From the Department of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY
| | - Aaqib Malik
- From the Department of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY
| | - Muhammad Shahzeb Khan
- Duke Clinical Research Institute, Durham, NC
- Division of Cardiology, Duke University School of Medicine, Durham, NC
| | - Amanda Lloji
- From the Department of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY
| | - Urvashi Hooda
- From the Department of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY
| | - Wilbert S Aronow
- From the Department of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY
| | - Gregg M Lanier
- From the Department of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY
| | - Stephen Pan
- From the Department of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY
| | - Stephen J Greene
- Duke Clinical Research Institute, Durham, NC
- Division of Cardiology, Duke University School of Medicine, Durham, NC
| | - M Hassan Murad
- Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, MN
| | - Erin D Michos
- Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Howard A Cooper
- From the Department of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY
| | - Alan Gass
- From the Department of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY
| | - Rahul Gupta
- Division of Cardiology, Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA
| | - Nihar R Desai
- Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT
| | - Robert J Mentz
- Duke Clinical Research Institute, Durham, NC
- Division of Cardiology, Duke University School of Medicine, Durham, NC
| | | | - Julio A Panza
- From the Department of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY
| |
Collapse
|
3
|
Affiliation(s)
- Julio A Panza
- Department of Cardiology, Westchester Medical Center, Valhalla, New York
- Department of Medicine, New York Medical College, Valhalla
| |
Collapse
|
4
|
Isath A, Panza JA. The Evolving Paradigm of Revascularization in Ischemic Cardiomyopathy: from Recovery of Systolic Function to Protection Against Future Ischemic Events. Curr Cardiol Rep 2023; 25:1513-1521. [PMID: 37874470 DOI: 10.1007/s11886-023-01977-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/03/2023] [Indexed: 10/25/2023]
Abstract
PURPOSE OF REVIEW We aim to reevaluate how the assessment of myocardial viability can guide optimal treatment strategies for patients with ischemic cardiomyopathy (ICM) based on a more contemporary understanding of the mechanism of benefit of revascularization. RECENT FINDINGS The assessment of viability in left ventricular (LV) segments with diminished contraction has been proposed as key to predict the benefit of revascularization and, therefore, as a requisite for the selection of patients to undergo this form of treatment. However, data from prospective trials have diverged from earlier retrospective studies. Traditional binary viability assessment may oversimplify ICM's complexity and the nuances of revascularization benefits. A conceptual shift from the traditional paradigm centered on the assessment of viability as a dichotomous variable to a more comprehensive approach encompassing a thorough understanding of ICM's complex pathophysiology and the salutary effect of revascularization in the prevention of myocardial infarction and ventricular arrhythmias is required.
Collapse
Affiliation(s)
- Ameesh Isath
- Department of Cardiology, Westchester Medical Center, 100 Woods Rd, Valhalla, NY, USA
| | - Julio A Panza
- Department of Cardiology, Westchester Medical Center, 100 Woods Rd, Valhalla, NY, USA.
- Department of Medicine, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY, USA.
| |
Collapse
|
5
|
Isath A, Lanier GM, Spielvogel D, Malekan R, Steinmetz C, Fishkin T, Semaan R, Panza JA, Naidu SS. OUTCOMES OF PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY AND PULMONARY HYPERTENSION UNDERGOING SEPTAL REDUCTION THERAPY STRATIFIED BY TREATMENT MODALITY. J Am Coll Cardiol 2023. [DOI: 10.1016/s0735-1097(23)00994-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
6
|
Isath A, Lanier GM, Spielvogel D, Malekan R, Steinmetz C, Semaan R, Fishkin T, Panza JA, Naidu SS. IMPACT OF PULMONARY HYPERTENSION ON SEPTAL REDUCTION THERAPY OUTCOMES FOR HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY. J Am Coll Cardiol 2023. [DOI: 10.1016/s0735-1097(23)00993-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
7
|
Farsky PS, White J, Al-Khalidi HR, Sueta CA, Rouleau JL, Panza JA, Velazquez EJ, O'Connor CM. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. J Thorac Cardiovasc Surg 2022; 164:1890-1899.e4. [PMID: 33610365 PMCID: PMC8260609 DOI: 10.1016/j.jtcvs.2020.12.094] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Revised: 12/02/2020] [Accepted: 12/14/2020] [Indexed: 01/06/2023]
Abstract
OBJECTIVES Optimal medical therapy in patients with heart failure and coronary artery disease is associated with improved outcomes. However, whether this association is influenced by the performance of coronary artery bypass grafting is less well established. Thus, the aim of this study was to determine the possible relationship between coronary artery bypass grafting and optimal medical therapy and its effect on the outcomes of patients with ischemic cardiomyopathy. METHODS The Surgical Treatment for Ischemic Heart Failure trial randomized 1212 patients with coronary artery disease and left ventricular ejection fraction 35% or less to coronary artery bypass grafting with medical therapy or medical therapy alone with a median follow-up over 9.8 years. For the purpose of this study, optimal medical therapy was collected at baseline and 4 months, and defined as the combination of 4 drugs: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, beta-blocker, statin, and 1 antiplatelet drug. RESULTS At baseline and 4 months, 58.7% and 73.3% of patients were receiving optimal medical therapy, respectively. These patients had no differences in important parameters such as left ventricular ejection fraction and left ventricular volumes. In a multivariable Cox model, optimal medical therapy at baseline was associated with a lower all-cause mortality (hazard ratio, 0.78; 95% confidence interval, 0.66-0.91; P = .001). When landmarked at 4 months, optimal medical therapy was also associated with a lower all-cause mortality (hazard ratio, 0.82; 95% confidence interval, 0.62-0.99; P = .04). There was no interaction between the benefit of optimal medical therapy and treatment allocation. CONCLUSIONS Optimal medical therapy was associated with improved long-term survival and lower cardiovascular mortality in patients with ischemic cardiomyopathy and should be strongly recommended.
Collapse
Affiliation(s)
- Pedro S Farsky
- Instituto Dante Pazzanese de Cardiologia and Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
| | - Jennifer White
- Duke Clinical Research Institute and Department of Biostatics and Bioinformatics, Duke University School of Medicine, Durham, NC
| | - Hussein R Al-Khalidi
- Duke Clinical Research Institute and Department of Biostatics and Bioinformatics, Duke University School of Medicine, Durham, NC
| | - Carla A Sueta
- Division of Cardiology, University of North Carolina, Chapel Hill, NC
| | - Jean L Rouleau
- Department of Medicine, Montréal Heart Institute, Université de Montréal, Montréal, Quebec, Canada
| | - Julio A Panza
- Westchester Medical Center and New York Medical College, Valhalla, NY
| | | | | |
Collapse
|
8
|
Levine A, Kai M, Ohira S, Panza JA, Pan S, Lanier G, Aggarwal-Gupta C, Gass A. Ecpella 5.5: An Evolution in the Management of Mechanical Circulatory Support. Cardiol Rev 2022; Publish Ahead of Print:CRD.0000000000000466. [PMID: 35713936 DOI: 10.1097/crd.0000000000000466] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
There are several endovascular options for temporary mechanical circulatory support in patients with refractory cardiogenic shock. These devices are often utilized in tandem to provide maximal support, including the combination of venoarterial extracorporeal membrane oxygenation with the Impella device, termed ECPELLA. An underappreciated characteristic of mechanical circulatory support is whether they provide cardiac "replacement" and/or cardiac "assistance." Within this framework, we propose an evolution in the approach to ECPELLA utilizing the Impella 5.5, with a focus on the Impella 5.5 as the primary support device.
Collapse
Affiliation(s)
- Avi Levine
- From the Department of Cardiology, Westchester Medical Center, Valhalla, NY
| | - Masashi Kai
- Department of Cardiothoracic Surgery, Westchester Medical Center, Valhalla, NY
| | - Suguru Ohira
- Department of Cardiothoracic Surgery, Westchester Medical Center, Valhalla, NY
| | - Julio A Panza
- From the Department of Cardiology, Westchester Medical Center, Valhalla, NY
| | - Stephen Pan
- From the Department of Cardiology, Westchester Medical Center, Valhalla, NY
| | - Gregg Lanier
- From the Department of Cardiology, Westchester Medical Center, Valhalla, NY
| | | | - Alan Gass
- From the Department of Cardiology, Westchester Medical Center, Valhalla, NY
| |
Collapse
|
9
|
Sharedalal P, Shah N, Sreenivasan J, Michaud L, Sharedalal A, Kaul R, Panza JA, Aronow WS, Cooper HA. Trends in 10-Year Predicted Risk of Cardiovascular Disease Associated With Food Insecurity, 2007-2016. Front Cardiovasc Med 2022; 9:851984. [PMID: 35686041 PMCID: PMC9170893 DOI: 10.3389/fcvm.2022.851984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 04/29/2022] [Indexed: 11/25/2022] Open
Abstract
Introduction Consumption of a healthy diet improves cardiovascular (CV) risk factors and reduces the development of cardiovascular disease (CVD). Food insecure (FIS) adults often consume an unhealthy diet, which can promote obesity, type 2 diabetes mellitus (T2DM), hypertension (HTN), and hyperlipidemia (HLD). The Supplemental Nutrition Assistance Program (SNAP) is designed to combat food insecurity by increasing access to healthy foods. However, there is a paucity of data on the association of SNAP participation among FIS adults and these CVD risk factors. Methods The National Health and Nutrition Examination Survey (NHANES) is a publicly available, ongoing survey administered by the Centers for Disease Control and Prevention and the National Center for Health Statistics. We analyzed five survey cycles (2007-2016) of adult participants who responded to the CVD risk profile questionnaire data. We estimated the burden of select CVD risk factors among the FIS population and the association with participation in SNAP. Results Among 10,449 adult participants of the survey, 3,485 (33.3%) identified themselves as FIS. Food insecurity was more common among those who were younger, female, Hispanic, and Black. Among the FIS, SNAP recipients, when compared to non-SNAP recipients, had a lower prevalence of HLD (36.3 vs. 40.1% p = 0.02), whereas rates of T2DM, HTN, and obesity were similar. Over the 10-year survey period, FIS SNAP recipients demonstrated a reduction in the prevalence of HTN (p < 0.001) and HLD (p < 0.001) which was not evident among those not receiving SNAP. However, obesity decreased only among those not receiving SNAP. The prevalence of T2DM did not change over the study period in either group. Conclusion Over a 10-year period, FIS adults who received SNAP demonstrated a reduction in the prevalence of HTN and HLD, which was not seen among those not receiving SNAP. However, the prevalence of obesity and T2DM did not decline among SNAP recipients, suggesting that additional approaches are required to impact these important CVD risk factors.
Collapse
Affiliation(s)
- Parija Sharedalal
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Neal Shah
- Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Jayakumar Sreenivasan
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Liana Michaud
- Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Anmol Sharedalal
- School of Medicine, St. George’s University, St. George’s, Grenada
| | - Risheek Kaul
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Julio A. Panza
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Wilbert S. Aronow
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Howard A. Cooper
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| |
Collapse
|
10
|
Chew DS, Cowper PA, Al-Khalidi H, Anstrom KJ, Daniels MR, Davidson-Ray L, Li Y, Michler RE, Panza JA, Piña IL, Rouleau JL, Velazquez EJ, Mark DB. Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. Circulation 2022; 145:819-828. [PMID: 35044802 PMCID: PMC8959089 DOI: 10.1161/circulationaha.121.056276] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure) demonstrated that coronary artery bypass grafting (CABG) reduced all-cause mortality rates out to 10 years compared with medical therapy alone (MED) in patients with ischemic cardiomyopathy and reduced left ventricular function (ejection fraction ≤35%). We examined the economic implications of these results. METHODS We used a decision-analytic patient-level simulation model to estimate the lifetime costs and benefits of CABG and MED using patient-level resource use and clinical data collected in the STICH trial. Patient-level costs were calculated by applying externally derived US cost weights to resource use counts during trial follow-up. A 3% discount rate was applied to both future costs and benefits. The primary outcome was the incremental cost-effectiveness ratio assessed from the US health care sector perspective. RESULTS For the CABG arm, we estimated 6.53 quality-adjusted life-years (95% CI, 5.70-7.53) and a lifetime cost of $140 059 (95% CI, $106 401 to $180 992). For the MED arm, the corresponding estimates were 5.52 (95% CI, 5.06-6.09) quality-adjusted life-years and $74 894 lifetime cost (95% CI, $58 372 to $93 541). The incremental cost-effectiveness ratio for CABG compared with MED was $63 989 per quality-adjusted life-year gained. At a societal willingness-to-pay threshold of $100 000 per quality-adjusted life-year gained, CABG was found to be economically favorable compared with MED in 87% of microsimulations. CONCLUSIONS In the STICH trial, in patients with ischemic cardiomyopathy and reduced left ventricular function, CABG was economically attractive relative to MED at current benchmarks for value in the United States. REGISTRATION URL: https://www. CLINICALTRIALS gov; Unique identifier: NCT00023595.
Collapse
Affiliation(s)
- Derek S Chew
- Duke Clinical Research Institute (D.S.C., P.A.C., H.A., K.J.A., M.R.D., L.D.-R., Y.L., D.B.M.), Duke University, Durham, NC.,Department of Cardiac Sciences, Libin Cardiovascular Institute (D.S.C.), University of Calgary, Alberta, Canada.,O'Brien Institute for Public Health (D.S.C.), University of Calgary, Alberta, Canada
| | - Patricia A Cowper
- Duke Clinical Research Institute (D.S.C., P.A.C., H.A., K.J.A., M.R.D., L.D.-R., Y.L., D.B.M.), Duke University, Durham, NC
| | - Hussein Al-Khalidi
- Duke Clinical Research Institute (D.S.C., P.A.C., H.A., K.J.A., M.R.D., L.D.-R., Y.L., D.B.M.), Duke University, Durham, NC.,Department of Biostatistics and Bioinformatics (H.A., K.J.A.), Duke University, Durham, NC
| | - Kevin J Anstrom
- Duke Clinical Research Institute (D.S.C., P.A.C., H.A., K.J.A., M.R.D., L.D.-R., Y.L., D.B.M.), Duke University, Durham, NC.,Department of Biostatistics and Bioinformatics (H.A., K.J.A.), Duke University, Durham, NC
| | - Melanie R Daniels
- Duke Clinical Research Institute (D.S.C., P.A.C., H.A., K.J.A., M.R.D., L.D.-R., Y.L., D.B.M.), Duke University, Durham, NC
| | - Linda Davidson-Ray
- Duke Clinical Research Institute (D.S.C., P.A.C., H.A., K.J.A., M.R.D., L.D.-R., Y.L., D.B.M.), Duke University, Durham, NC
| | - Yanhong Li
- Duke Clinical Research Institute (D.S.C., P.A.C., H.A., K.J.A., M.R.D., L.D.-R., Y.L., D.B.M.), Duke University, Durham, NC
| | - Robert E Michler
- Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Bronx, NY (R.E.M.)
| | - Julio A Panza
- Department of Cardiology, Westchester Medical Center, Westchester Medical Center Health Network, Valhalla, NY (J.A.P.)
| | - Ileana L Piña
- Department of Medicine, Wayne State University, Detroit, MI (I.L.P.)
| | - Jean L Rouleau
- Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.)
| | - Eric J Velazquez
- Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT (E.J.V.)
| | - Daniel B Mark
- Duke Clinical Research Institute (D.S.C., P.A.C., H.A., K.J.A., M.R.D., L.D.-R., Y.L., D.B.M.), Duke University, Durham, NC.,Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC (D.B.M.)
| | | |
Collapse
|
11
|
Yandrapalli S, Harikrishnan P, Andries G, Aronow WS, Panza JA, Naidu SS. Differences in Short-Term Outcomes and Hospital-Based Resource Utilization Between Septal Reduction Strategies for Hypertrophic Obstructive Cardiomyopathy. J Invasive Cardiol 2022; 34:E8-E13. [PMID: 34919530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
BACKGROUND Given clinical equipoise in a subset of obstructive hypertrophic cardiomyopathy (OHCM) patients who are candidates for both alcohol septal ablation (ASA) or septal myectomy (SM), other considerations such as cost, readmissions, and hospital length of stay (LOS) may be important to optimize healthcare resource utilization and inform shared decision making. METHODS In this retrospective observational analysis of the United States Nationwide Readmissions Database years 2012-2014, we identified adults who underwent isolated septal reduction (SR) for OHCM. We studied the differences in short-term outcomes (inpatient mortality and 90-day readmission rate) and in-hospital resource utilization (LOS and costs) between the SR strategies. RESULTS Of the 2250 patients in this study, ASA was performed in 1113 (49.5%) and SM in 1137 (50.5%). Inpatient mortality occurred in 21 patients (0.9%), with similar rates between strategies (10 SM patients [0.9%] vs 11 ASA patients [1.0%]; P=.30). Of the 2229 patients who survived to discharge, 298 (13.4%) were readmitted 386 times within 90 days with a similar readmission rate between SM (14.9%) and ASA (11.8%; P=.16). During the index admission, average LOS and cost were significantly lower for ASA (3.9 days, United States [US] $20,322) compared with SM (7.6 days, US $39,470; P<.001). Average LOS and cost during 90-day readmissions were similar between ASA and SM. Combining index admissions and readmissions, patients undergoing ASA had significantly lower LOS and hospitalization costs. CONCLUSIONS In this non-randomized observational study of OHCM patients undergoing isolated septal reduction, ASA was associated with similar short-term outcomes, including mortality, but substantially lower hospitalization costs and LOS compared with SM.
Collapse
Affiliation(s)
- Srikanth Yandrapalli
- Department of Cardiology, Westchester Medical Center and New York Medical College, 100 Woods Rd, Macy Pavilion, Valhalla, NY 10595 USA.
| | | | | | | | | | | |
Collapse
|
12
|
Yandrapalli S, Malik AH, Namrata F, Pemmasani G, Bandyopadhyay D, Vallabhajosyula S, Aronow WS, Frishman WH, Jain D, Cooper HA, Panza JA. Influence of diabetes mellitus interactions with cardiovascular risk factors on post-myocardial infarction heart failure hospitalizations. Int J Cardiol 2021; 348:140-146. [PMID: 34864085 DOI: 10.1016/j.ijcard.2021.11.086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 11/01/2021] [Accepted: 11/29/2021] [Indexed: 11/25/2022]
Abstract
OBJECTIVE There is a paucity of information regarding how cardiovascular risk factors (RF) modulate the impact of diabetes mellitus (DM) on the heart failure hospitalization (HFH) risk following an acute myocardial infarction (AMI). METHODS Adult survivors of an AMI were retrospectively identified from the 2014 US Nationwide Readmissions Database. The impact of DM on the risk for a 6-month HFH was studied in subgroups of RFs using multivariable logistic regression to adjust for baseline risk differences. Individual interactions of DM with RFs were tested. RESULTS Of 237,549 AMI survivors, 37.2% patients had DM. Primary outcome occurred in 12,934 patients (5.4%), at a 106% higher rate in DM patients (7.9% vs 4.0%, p < 0.001), which was attenuated to a 45% higher adjusted risk. Higher HFH risk in DM patients was consistent across subgroups and significant interactions were present between DM and other RFs. The increased HFH risk with DM was more pronounced in patients without certain HF RFs compared with those with these RFs [age < 65: OR for DM 1.84 (1.58-2.13) vs age ≥ 65: OR 1.34 (1.24-1.45); HF absent during index AMI: OR for DM 1.87 (1.66-2.10) vs HF present: OR 1.24 (1.14-1.34); atrial fibrillation absent: OR for DM 1.57 (1.46-1.68) vs present: OR 1.19 (1.06-1.33); Pinteraction < 0.001 for all]. Similar results were noted for hypertension and chronic kidney disease. CONCLUSIONS AMI survivors with DM had a higher risk of 6-month HFHs. The impact of DM on the increased HFH risk was more pronounced in patients without certain RFs suggesting that more aggressive preventive strategies related to DM and HF are needed in these subgroups to prevent or delay the onset of HFHs.
Collapse
Affiliation(s)
- Srikanth Yandrapalli
- Division of Cardiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
| | - Aaqib H Malik
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Fnu Namrata
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Gayatri Pemmasani
- Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Dhrubajyoti Bandyopadhyay
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | | | - Wilbert S Aronow
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - William H Frishman
- Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Diwakar Jain
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Howard A Cooper
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Julio A Panza
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| |
Collapse
|
13
|
Kaul R, Sreenivasan J, Goel A, Malik A, Bandyopadhyay D, Jin C, Sharma M, Levine A, Pan S, Fuisz A, Cooper HA, Panza JA. Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc 2021; 36:100872. [PMID: 34568540 PMCID: PMC8450283 DOI: 10.1016/j.ijcha.2021.100872] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 09/06/2021] [Accepted: 09/08/2021] [Indexed: 12/30/2022]
Affiliation(s)
- Risheek Kaul
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Jayakumar Sreenivasan
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Akshay Goel
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Aaqib Malik
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Dhrubajyoti Bandyopadhyay
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Chengyue Jin
- Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Mala Sharma
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Avi Levine
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Stephen Pan
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Anthon Fuisz
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Howard A Cooper
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| | - Julio A Panza
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, United States
| |
Collapse
|
14
|
Sreenivasan J, Abu-Haniyeh A, Hooda U, Khan MS, Aronow WS, Michos ED, Cooper HA, Panza JA. Rate, causes, and predictors of 90-day readmissions and the association with index hospitalization coronary revascularization following non-ST elevation myocardial infarction in the United States. Catheter Cardiovasc Interv 2021; 98:12-21. [PMID: 32686892 DOI: 10.1002/ccd.29119] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Accepted: 06/07/2020] [Indexed: 11/05/2022]
Abstract
OBJECTIVES To assess the causes and predictors of readmission after NSTEMI. BACKGROUND Studies on readmissions following non-ST elevation myocardial infarction (NSTEMI) are limited. We investigated the rate and causes for readmission and the impact of coronary revascularization on 90-day readmissions following a hospitalization for NSTEMI in a large, nationally representative United States database. METHODS We queried the National Readmission Database for the year 2016 using appropriate ICD-10-CM/PCS codes to identify all adult admissions for NSTEMI. We determined the 90-day readmissions for major adverse cardiac events (MACE). All-cause readmission was a secondary endpoint. The association between coronary revascularization and the likelihood of readmission was analyzed using multivariate Cox regression analysis. RESULTS A total of 296,965 adult discharges following an admission for NSTEMI were included in this study. The rate of readmissions for MACE was 5.2% (n = 15,637) and for any cause was 18.0% (n = 53,316). 38% of MACE readmissions and 40% of all-cause readmissions occurred between 30- and 90-days following the index hospitalization. During index hospitalization, 51.0% underwent coronary revascularization (40.8% with PCI and 10.2% with CABG). This was independently predictive of a lower risk of 90-day readmission for MACE (adjusted HR 0.59, 95% confidence interval (CI) 0.56-0.63, p < .001) and for any cause (adjusted HR 0.65, 95% CI 0.63-0.67, p < .001). In-hospital mortality for MACE readmissions was significantly higher compared to that of index hospitalization (3.8% vs. 2.6%, p < .001). CONCLUSION Readmissions following NSTEMI carry higher mortality than the index hospitalization. Coronary revascularization for NSTEMI is associated with a lower readmission rate at 90 days.
Collapse
Affiliation(s)
- Jayakumar Sreenivasan
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Ahmed Abu-Haniyeh
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Urvashi Hooda
- Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY
| | | | - Wilbert S Aronow
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Erin D Michos
- Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Howard A Cooper
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Julio A Panza
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| |
Collapse
|
15
|
Malik AH, Yandrapalli S, Shetty SS, Zaid S, Athar A, Aronow WS, Timmermans RJ, Ahmad H, Cooper HA, Naidu SS, Panza JA. Radial vs. Femoral Access for Percutaneous Coronary Artery Intervention in Patients With ST-Elevation Myocardial Infarction. Cardiovasc Revasc Med 2021; 28:57-64. [PMID: 32981856 DOI: 10.1016/j.carrev.2020.06.039] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 05/27/2020] [Accepted: 06/15/2020] [Indexed: 12/28/2022]
Abstract
BACKGROUND We aimed to compare the safety and efficacy of transradial vs transfemoral access for coronary angiography and intervention in patients presenting with ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock. METHODS PubMed, Embase and Cochrane Central were searched for randomized controlled trials (RCTs) comparing outcomes of STEMI patients who underwent transradial angiography (TRA) compared to transfemoral angiography (TFA). Our outcomes of interest were major adverse cardiac events (MACE), all-cause mortality, severe bleeding, access site bleeding, myocardial infarction, stroke, and major vascular complications. Summary statistics are reported as odds ratios (OR) with 95% confidence intervals (CI). RESULTS In a pooled analysis of 17 RCTs with 12,118 randomized patients, the use of transradial compared to transfemoral approach in STEMI patients without cardiogenic shock was associated with a significant reduction in MACE [OR 0.85 (95% CI 0.73-0.99; p = 0.04; NNT = 111; I2 = 0%)] and all-cause mortality [OR 0.71 (95% CI 0.57-0.88; p < 0.01; NNT = 111; I2 = 0%)]. Severe bleeding [OR 0.57 (95% CI 0.44-0.74; p < 0.01; NNT = 77; I2 = 0%)], access-site bleeding [OR 0.39 (95% CI 0.26-0.59; p < 0.01; NNT = 67; I2 = 24%)], and major vascular complications [OR of 0.31 (95% CI 0.17-0.55; p < 0.01; NNT = 125; I2 = 0%)] were lower in TRA compared to TFA. There was no difference in stroke (0.6% vs 0.5%) or recurrent myocardial infarction (2.01% vs 2.02%) between the two approaches. CONCLUSIONS For coronary intervention in STEMI patients without cardiogenic shock, there is a clear mortality benefit with the TRA over TFA. Further studies are needed to see if this mortality benefit persists over the long-term.
Collapse
Affiliation(s)
- Aaqib H Malik
- Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.
| | - Srikanth Yandrapalli
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Suchith S Shetty
- Division of Cardiology, Department of Internal Medicine, University of Iowa Health Care, Carver College of Medicine, Iowa City, USA
| | - Syed Zaid
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Ammar Athar
- Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Wilbert S Aronow
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Robert J Timmermans
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Hasan Ahmad
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Howard A Cooper
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Srihari S Naidu
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Julio A Panza
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| |
Collapse
|
16
|
Sreenivasan J, Kaul R, Khan MS, Ranka S, Demmer RT, Yuzefpolskaya M, Aronow WS, Warraich HJ, Pan S, Panza JA, Cooper HA, Naidu SS, Colombo PC. Left Ventricular Assist Device Implantation in Hypertrophic and Restrictive Cardiomyopathy: A Systematic Review. ASAIO J 2021; 67:239-244. [PMID: 33627595 DOI: 10.1097/mat.0000000000001238] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Left ventricular assist device (LVAD) implantation in patients with advanced heart failure due to hypertrophic or restrictive cardiomyopathy (HCM/RCM) presents technical and physiologic challenges. We conducted a systematic review of observational studies to evaluate the utilization and clinical outcomes associated with LVAD implantation in patients with HCM/RCM and compared these to patients with dilated or ischemic cardiomyopathy (DCM/ICM). We searched MEDLINE, EMBASE, and Scopus from inception through May 2019 and included appropriate studies describing the use of an LVAD in patients with HCM/RCM. We identified six studies with a total of 2,766 patients with HCM/RCM and advanced heart failure, among whom 338 patients (12.2%) underwent LVAD implantation. In patients listed for transplant, the rate of LVAD implantation was significantly lower in patients with HCM/RCM compared to that in patients with DCM/ICM (4.4% vs. 18.2%, p < 0.001). Adverse clinical outcomes were significantly higher in HCM/RCM than in DCM/ICM, including operative/short-term mortality (14.0% vs. 9.0%), right ventricular failure (50.0% vs. 21.0%), infection (15.5% vs. 11.2%), bleeding (40.2% vs. 12.5%), renal failure (15.0% vs. 5.1%), stroke (5.0% vs. 2.4%), and arrhythmias (18.0% vs. 7.7%) (all p values <0.001).
Collapse
Affiliation(s)
- Jayakumar Sreenivasan
- From the Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Risheek Kaul
- From the Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Muhammad Shahzeb Khan
- Department of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
| | - Sagar Ranka
- Division of Cardiovascular Medicine, Kansas University Medical Center, Kansas City, KS
| | - Ryan T Demmer
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN
| | - Melana Yuzefpolskaya
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
| | - Wilbert S Aronow
- From the Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Haider J Warraich
- Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.,Department of Medicine, Cardiology Section, VA Boston Healthcare System, Boston, MA
| | - Stephen Pan
- From the Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Julio A Panza
- From the Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Howard A Cooper
- From the Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Srihari S Naidu
- From the Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Paolo C Colombo
- From the Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| |
Collapse
|
17
|
Sreenivasan J, Khan MS, Khan SU, Hooda U, Aronow WS, Panza JA, Levine GN, Commodore-Mensah Y, Blumenthal RS, Michos ED. Mental health disorders among patients with acute myocardial infarction in the United States. Am J Prev Cardiol 2021; 5:100133. [PMID: 34327485 PMCID: PMC8315415 DOI: 10.1016/j.ajpc.2020.100133] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2020] [Revised: 11/22/2020] [Accepted: 11/27/2020] [Indexed: 02/07/2023] Open
Abstract
OBJECTIVE To assess the prevalence, temporal trends and sex- and racial/ethnic differences in the burden of mental health disorders (MHD) and outcomes among patients with myocardial infarction (MI) in the United States. METHODS Using the National Inpatient Sample Database, we evaluated a contemporary cohort of patients hospitalized for acute MI in the United States over 10 years period from 2008 to 2017. We used multivariable logistic regression analysis for in-hospital outcomes, yearly trends and estimated annual percent change (APC) in odds of MHD among MI patients. RESULTS We included a total sample of 6,117,804 hospitalizations for MI (ST elevation MI in 30.4%), with a mean age of 67.2 ± 0.04 years and 39% females. Major depression (6.2%) and anxiety disorders (6.0%) were the most common MHD, followed by bipolar disorder (0.9%), schizophrenia/psychotic disorders (0.8%) and post-traumatic stress disorder (PTSD) (0.3%). Between 2008 and 2017, the prevalences significantly increased for major depression (4.7%-7.4%, APC +6.2%, p < .001), anxiety disorders (3.2%-8.9%, APC +13.5%, p < .001), PTSD (0.2%-0.6%, +12.5%, p < .001) and bipolar disorder (0.7%-1.0%, APC +4.0%, p < .001). Significant sex- and racial/ethnic-differences were also noted. Major depression, bipolar disorder or schizophrenia/psychotic disorders were associated with a lower likelihood of coronary revascularization. CONCLUSION MHD are common among patients with acute MI and there was a concerning increase in the prevalence of major depression, bipolar disorder, anxiety disorders and PTSD over this 10-year period. Focused mental health interventions are warranted to address the increasing burden of comorbid MHD among acute MI.
Collapse
Affiliation(s)
- Jayakumar Sreenivasan
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | | | - Safi U. Khan
- Department of Medicine, West Virginia University, Morgantown, WV, USA
| | - Urvashi Hooda
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Wilbert S. Aronow
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Julio A. Panza
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Glenn N. Levine
- Division of Cardiology, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, USA
| | - Yvonne Commodore-Mensah
- Johns Hopkins University School of Nursing, Bloomberg School of Public Health, Baltimore, MD, USA
| | - Roger S. Blumenthal
- Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Erin D. Michos
- Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
18
|
Sreenivasan J, Khan MS, Kaul R, Bandyopadhyay D, Hooda U, Aronow WS, Cooper HA, Panza JA, Naidu SS. Sex Differences in the Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy. JACC Cardiovasc Interv 2021; 14:930-932. [PMID: 33454297 DOI: 10.1016/j.jcin.2020.10.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 09/21/2020] [Accepted: 10/06/2020] [Indexed: 10/22/2022]
|
19
|
O'Fee K, Panza JA, Brown DL. Association of Inducible Myocardial Ischemia With Long-Term Mortality and Benefit From Coronary Artery Bypass Graft Surgery in Ischemic Cardiomyopathy: Ten-Year Follow-Up of the STICH Trial. Circulation 2021; 143:205-207. [PMID: 33428429 DOI: 10.1161/circulationaha.120.050734] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Kevin O'Fee
- Cardiovascular Division, Washington University School of Medicine, St Louis, MO (K.O., D.L.B.)
| | - Julio A Panza
- Department of Cardiology, Westchester Medical Center, Valhalla, NY (J.A.P.).,New York Medical College, Valhalla (J.A.P.)
| | - David L Brown
- Cardiovascular Division, Washington University School of Medicine, St Louis, MO (K.O., D.L.B.)
| |
Collapse
|
20
|
Sreenivasan J, Khan MS, Hooda U, Khan SU, Aronow WS, Mookadam F, Krasuski RA, Cooper HA, Michos ED, Panza JA. Rate, Causes, and Predictors of 30-Day Readmission Following Hospitalization for Acute Pericarditis. Am J Med 2020; 133:1453-1459.e1. [PMID: 32598902 DOI: 10.1016/j.amjmed.2020.05.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 04/23/2020] [Accepted: 05/19/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND Acute pericarditis is a frequent cause of hospitalization in the United States. Although recurrence of this condition is common, few studies have investigated hospital readmissions in this patient population. METHODS We queried the National Readmission Database for the years 2016 and 2017 to identify adult admissions for acute pericarditis, and analyzed the data for 30-day readmission. Using multivariate Cox regression analysis, we identified clinical characteristics that were independently predictive of hospital readmission within 30 days. RESULTS A total of 21,335 patients (mean age 52.5 ± 0.2 years; 38.3% women) who were discharged following hospitalization for acute pericarditis were included. The rate of 30-day readmission was 12.9% (n = 2740). Increasing age (adjusted hazard ratio [HR] 1.05 per 5-year increase; 95% confidence interval [CI], 1.02-1.09; P < 0.001), female sex (adjusted HR 1.33; 95% CI, 1.18-1.49; P < 0.001), dialysis dependence (adjusted HR 1.70; 95% CI, 1.30-2.22; P < 0.001), chronic obstructive pulmonary disease (adjusted HR 1.27; 95% CI, 1.11-1.45; P < 0.001), and presence of pericardial effusion (adjusted HR 1.24; 95% CI, 1.04-1.49; P = 0.02) were independently associated with a higher risk of readmission. In-hospital mortality was significantly higher after readmission than for the index hospitalization (3.4% vs 1.0%, P < 0.001). CONCLUSION After hospitalization for acute pericarditis, readmission within 30 days is common and is associated with increased mortality. Identification of characteristics associated with a higher risk of readmission may lead to focused interventions to improve outcomes.
Collapse
Affiliation(s)
- Jayakumar Sreenivasan
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY.
| | | | - Urvashi Hooda
- Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Safi U Khan
- Department of Medicine, West Virginia University, Morgantown
| | - Wilbert S Aronow
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | | | | | - Howard A Cooper
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| | - Erin D Michos
- Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD
| | - Julio A Panza
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY
| |
Collapse
|
21
|
Yandrapalli S, Malik AH, Pemmasani G, Gupta K, Harikrishnan P, Nabors C, Aronow WS, Cooper HA, Panza JA, Frishman WH, Jain D. Risk Factors and Outcomes During a First Acute Myocardial Infarction in Breast Cancer Survivors Compared with Females Without Breast Cancer. Am J Med 2020; 133:444-451. [PMID: 31715170 DOI: 10.1016/j.amjmed.2019.10.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Revised: 09/06/2019] [Accepted: 10/09/2019] [Indexed: 01/04/2023]
Abstract
PURPOSE The purpose of this research was to study the differences in epidemiology and outcomes of a first myocardial infarction in breast cancer survivors compared with the general female population in the United States. METHODS We retrospectively analyzed the US National Inpatient Sample years 2005-2015 to identify adult women with a first myocardial infarction. In this cohort, breast cancer survivors were identified. Outcomes evaluated were the differences in baseline demographics, comorbidities, and adjusted in-hospital mortality in women with and without breast cancer. RESULTS Among 1,644,032 first myocardial infarction cases in adult women, there were 56,842 (3.5%) breast cancer survivors. Compared with women without breast cancer, breast cancer survivors were 6 years older (mean age 77 vs 71 years, P < .001), had significantly higher prevalence of dyslipidemia and hypertension, and lower prevalence of obesity, diabetes mellitus, and smoking. Breast cancer survivors were more likely to have a non-ST segment elevation acute myocardial infarction and less likely to receive mechanical revascularization. In-hospital mortality was lower in breast cancer survivors (7.1%) compared with those without (7.9%, P < .001), findings that persisted after risk adjustment (odds ratio 0.89; 95% CI, 0.82-0.94). CONCLUSIONS Breast cancer survivors had a first acute myocardial infarction at an older age and had small but favorable differences in cardiovascular disease risk factors and outcomes compared with women without breast cancer. The favorable impact of health education, preventative medical care, greater motivation for a healthier lifestyle, and participation in cancer survivorship programs on these seemingly paradoxical findings in breast cancer survivors should be further explored.
Collapse
Affiliation(s)
| | - Aaqib H Malik
- Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY
| | | | | | | | - Christopher Nabors
- Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY
| | | | | | | | - William H Frishman
- Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY
| | | |
Collapse
|
22
|
Malik AH, Yandrapalli S, Shetty S, Aronow WS, Jain D, Frishman WH, Cooper HA, Panza JA. Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis. Europace 2020; 22:361-367. [PMID: 31985781 DOI: 10.1093/europace/euz361] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 11/05/2019] [Accepted: 12/13/2019] [Indexed: 09/20/2023] Open
Abstract
AIMS This study sought to determine the impact of weight and body mass index (BMI) on the safety and efficacy of direct-acting oral anticoagulants (DOACs) compared with warfarin in patients with non-valvular atrial fibrillation. METHODS AND RESULTS A systematic literature search was employed in PubMed, Embase, and Cochrane clinical trials with no language or date restrictions. Randomized trials or their substudies were assessed for relevant outcome data for efficacy that included stroke or systemic embolization (SSE), and safety including major bleeding and all-cause mortality. Binary outcome data and odds ratios from the relevant articles were used to calculate the pooled relative risk. For SSE, the data from the four Phase III trials showed that DOACs are better or similarly effective with low BMI 0.73 (0.56-0.97), normal BMI 0.72 (0.58-0.91), overweight 0.87 (0.76-0.99), and obese 0.87 (0.76-1.00). The risk of major bleeding was also better or similar with DOACs in all BMI subgroups with low BMI 0.62 (0.37-1.05), normal BMI 0.72 (0.58-0.90), overweight 0.83 (0.71-0.96), and obese 0.91 (0.81-1.03). There was no impact on mortality in all the subgroups. In a meta-regression analysis, the effect size advantage of DOACs compared with warfarin in terms of safety and efficacy gradually attenuated with increasing weight. CONCLUSION Our findings suggest that a weight-based dosage adjustment may be necessary to achieve optimal benefits of DOACs for thromboembolic prevention in these patients with non-valvular atrial fibrillation. Further dedicated trials are needed to confirm these findings. PROSPERO 2019 CRD42019140693. Available from: https://www.crd.york.ac.uk/prospero/display_record.php? ID=CRD42019140693.
Collapse
Affiliation(s)
- Aaqib H Malik
- Department of Medicine, Westchester Medical Center, New York Medical College, 100 Woods Road, Valhalla, NY 10595, USA
| | - Srikanth Yandrapalli
- Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Suchith Shetty
- Department of Medicine, University of Iowa Healthcare, Carver College of Medicine, Iowa City, IA, USA
| | - Wilbert S Aronow
- Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Diwakar Jain
- Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - William H Frishman
- Department of Medicine, Westchester Medical Center, New York Medical College, 100 Woods Road, Valhalla, NY 10595, USA
| | - Howard A Cooper
- Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Julio A Panza
- Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| |
Collapse
|
23
|
Andersson B, She L, Tan RS, Jeemon P, Mokrzycki K, Siepe M, Romanov A, Favaloro LE, Djokovic LT, Raju PK, Betlejewski P, Racine N, Ostrzycki A, Nawarawong W, Das S, Rouleau JL, Sopko G, Lee KL, Velazquez EJ, Panza JA. The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial. Eur Heart J 2019; 39:3464-3471. [PMID: 30113633 DOI: 10.1093/eurheartj/ehy438] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Accepted: 07/06/2018] [Indexed: 12/11/2022] Open
Abstract
Aims Hypertension (HTN) is a well-known contributor to cardiovascular disease, including heart failure (HF) and coronary artery disease, and is the leading risk factor for premature death world-wide. A J- or U-shaped relationship has been suggested between blood pressure (BP) and clinical outcomes in different studies. However, there is little information about the significance of BP on the outcomes of patients with coronary artery disease and left ventricular dysfunction. This study aimed to determine the relationship between BP and mortality outcomes in patients with ischaemic cardiomyopathy. Methods and results The influence of BP during a median follow-up of 9.8 years was studied in a total of 1212 patients with ejection fraction ≤35% and coronary disease amenable to coronary artery bypass grafting (CABG) who were randomized to CABG or medical therapy alone (MED) in the STICH (Surgical Treatment for Ischaemic Heart Failure) trial. Landmark analyses were performed starting at 1, 2, 3, 4, and 5 years after randomization, in which previous systolic BP values were averaged and related to subsequent mortality through the end of follow-up with a median of 9.8 years. Neither a previous history of HTN nor baseline BP had any significant influence on long-term mortality outcomes, nor did they have a significant interaction with MED or CABG treatment. The landmark analyses showed a progressive U-shaped relationship that became strongest at 5 years (χ2 and P-values: 7.08, P = 0.069; 8.72, P = 0.033; 9.86; P = 0.020; 8.31, P = 0.040; 14.52, P = 0.002; at 1, 2, 3, 4, and 5-year landmark analyses, respectively). The relationship between diastolic BP (DBP) and outcomes was similar. The most favourable outcomes were observed in the SBP range 120-130, and DBP 75-85 mmHg, whereas lower and higher BP were associated with worse outcomes. There were no differences in BP-lowering medications between groups. Conclusion A strong U-shaped relationship between BP and mortality outcomes was evident in ischaemic HF patients. The results imply that the optimal SBP might be in the range 120-130 mmHg after intervention, and possibly be subject to pharmacologic action regarding high BP. Further, low BP was a marker of poor outcomes that might require other interactions and treatment strategies. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.
Collapse
Affiliation(s)
- Bert Andersson
- Department of Cardiology, Blå Stråket 3, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Lilin She
- Duke Clinical Research Institute, 2400 Pratt Street Durham, NC, USA
| | - Ru-San Tan
- National Heart Centre, 5 Hospital Drive, Singapore
| | - Panniyammakal Jeemon
- Achutha Menon Centre for Health Science Studies, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum 695011, India, and Centre for Chronic Disease Control, New Delhi, India
| | - Krzysztof Mokrzycki
- Department of Cardiac Surgery, SPSK-2, Pomeranian Medical University, Powstanców Wielkopolskich 72, Szczecin, Poland
| | - Matthias Siepe
- Klinik für Herz- und Gefässchirurgie, Universitäts Herzzentrum Freiburg Bad Krozingen, Südring 15, Bad Krozingen, Germany
| | - Alexander Romanov
- Arrhythmia Department and Electrophysiology Laboratory, State Research Institute of Circulation Pathology, Rechkunovskaya 15, Novosibirsk, Russia
| | - Liliana E Favaloro
- Hospital Universitario Fundación Favaloro, Av. Belgrano 1782 (C1093AAS), Ciudad Autónoma de Buenos Aires, Argentina
| | - Ljubomir T Djokovic
- Dedinje Cardiovascular Institute, Heroja Milana Tepica br. 1, Belgrade, Serbia
| | - P Krishnam Raju
- Care Hospitals, Care op center, Road Number 10, Zahara Nagar, Banjara Hills, Hyderabad, Telangana, India
| | - Piotr Betlejewski
- Klinika Kardiochirurgii, Instytut Kardiologii, Wilenska 44, Gdansk, Poland
| | - Normand Racine
- Université de Montréal, Montréal Heart Institute, 5000 Belanger est, Montreal, Québec, Canada
| | - Adam Ostrzycki
- National Institute of Cardiology, Alpejska 42, Warsaw, Poland
| | - Weerachai Nawarawong
- Department of Surgery, Chiang Mai University, Su Thep, Mueang Chiang Mai District, Chiang Mai, Thailand
| | - Siuli Das
- Centre for Chronic Disease Conrol, C1/52 2nd Floor, Safdarjung Development Area, New Delhi, India
| | - Jean L Rouleau
- Université de Montréal, Montréal Heart Institute, 5000 Belanger est, Montreal, Québec, Canada
| | - George Sopko
- National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Dr, Bethesda, MD, USA
| | - Kerry L Lee
- Duke Clinical Research Institute, 2400 Pratt Street Durham, NC, USA.,Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA
| | - Eric J Velazquez
- Duke Clinical Research Institute, 2400 Pratt Street Durham, NC, USA.,Department of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Julio A Panza
- Cardiology, Westchester Medical Center and WMC Health Network, New York Medical College, 100 Woods Road, Macy Pavilion, Room 100 Valhalla, NY, USA
| |
Collapse
|
24
|
Malik AH, Yandrapalli S, Aronow WS, Jain D, Panza JA, Cooper HA. P4994Severe hypoglycemia: a marker for worse cardiovascular outcomes? A meta-analysis of randomised controlled trials. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Observational data have suggested that severe hypoglycemic events increase the risk of subsequent cardiovascular morbidity and mortality but the evidence from randomised studies has been inconsistent.
Purpose
This meta-analysis evaluates the relationship between severe hypoglycemic events (SHEs) and the subsequent risk of mortality and major adverse cardiovascular events (MACE).
Methods
PubMed, Embase, and Cochrane Central databases were searched for randomised controlled trials (RCTs) that reported cardiovascular outcomes in patients with diabetes with a history of SHE. Treatment effects and relative standard errors were calculated from the available data. These values were imputed in software R to perform meta-analysis via generic inverse variance method.
Results
Data from 9 RCTs and 3,462 randomised patients were available. Patients, who suffered a SHE, were found to have a significantly increased risk of subsequent all-cause mortality (HR 2.24; 95% CI 1.70, 2.95; p-value <0.01), cardiovascular mortality (HR 2.32; 95% CI 1.67, 3.22; p-value <0.01), and MACE (HR 1.66; 95% CI 1.35, 2.06; p-value <0.01) compared to the patients without a SHE. An increased risk of subsequent stroke and arrhythmic death (p-value<0.05) were also found. There was no significant association between SHE and the risk of subsequent myocardial infarction and hospitalisation for unstable angina or heart failure.
Predictors of severe hypoglycemia Older age, Lower weight, Insulin-treated, CKD, Neuropathy, previous CVD Older age, Females, Lower weight, Insulin-treated, Longer duration of diabetes, CKD, Previous CVD Older age, Females, Lower weight, Insulin-treated, Longer duration of diabetes, CKD, Previous CVD Older age, Females, Insulin-treated, Longer duration of diabetes, CKD Older age, Females, Lower weight, Insulin-treated, CKD Older age, Lower weight, Longer duration of diabetes, CKD, Poor cognition, Previous CVD CKD = Chronic kidney disease; CVD = Cardiovascular disease.
Conclusion
In patients with diabetes, the occurrence of a SHE was associated with a significantly increased risk of subsequent cardiovascular morbidity and mortality. Further studies are required to explore and circumvent the predictors of SHEs in these patients.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- A H Malik
- New York Medical College, Internal medicine, Valhalla, United States of America
| | - S Yandrapalli
- New York Medical College, New York, United States of America
| | - W S Aronow
- New York Medical College, New York, United States of America
| | - D Jain
- New York Medical College, New York, United States of America
| | - J A Panza
- New York Medical College, New York, United States of America
| | - H A Cooper
- New York Medical College, New York, United States of America
| |
Collapse
|
25
|
Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, Pohost GM, Sopko G, Chrzanowski L, Mark DB, Kukulski T, Favaloro LE, Maurer G, Farsky PS, Tan RS, Asch FM, Velazquez EJ, Rouleau JL, Lee KL, Bonow RO. Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. N Engl J Med 2019; 381:739-748. [PMID: 31433921 PMCID: PMC6814246 DOI: 10.1056/nejmoa1807365] [Citation(s) in RCA: 159] [Impact Index Per Article: 31.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND The role of assessment of myocardial viability in identifying patients with ischemic cardiomyopathy who might benefit from surgical revascularization remains controversial. Furthermore, although improvement in left ventricular function is one of the goals of revascularization, its relationship to subsequent outcomes is unclear. METHODS Among 601 patients who had coronary artery disease that was amenable to coronary-artery bypass grafting (CABG) and who had a left ventricular ejection fraction of 35% or lower, we prospectively assessed myocardial viability using single-photon-emission computed tomography, dobutamine echocardiography, or both. Patients were randomly assigned to undergo CABG and receive medical therapy or to receive medical therapy alone. Left ventricular ejection fraction was measured at baseline and after 4 months of follow-up in 318 patients. The primary end point was death from any cause. The median duration of follow-up was 10.4 years. RESULTS CABG plus medical therapy was associated with a lower incidence of death from any cause than medical therapy alone (182 deaths among 298 patients in the CABG group vs. 209 deaths among 303 patients in the medical-therapy group; adjusted hazard ratio, 0.73; 95% confidence interval, 0.60 to 0.90). However, no significant interaction was observed between the presence or absence of myocardial viability and the beneficial effect of CABG plus medical therapy over medical therapy alone (P = 0.34 for interaction). An increase in left ventricular ejection fraction was observed only among patients with myocardial viability, irrespective of treatment assignment. There was no association between changes in left ventricular ejection fraction and subsequent death. CONCLUSIONS The findings of this study do not support the concept that myocardial viability is associated with a long-term benefit of CABG in patients with ischemic cardiomyopathy. The presence of viable myocardium was associated with improvement in left ventricular systolic function, irrespective of treatment, but such improvement was not related to long-term survival. (Funded by the National Institutes of Health; STICH ClinicalTrials.gov number, NCT00023595.).
Collapse
Affiliation(s)
- Julio A Panza
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Alicia M Ellis
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Hussein R Al-Khalidi
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Thomas A Holly
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Daniel S Berman
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Jae K Oh
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Gerald M Pohost
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - George Sopko
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Lukasz Chrzanowski
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Daniel B Mark
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Tomasz Kukulski
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Liliana E Favaloro
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Gerald Maurer
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Pedro S Farsky
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Ru-San Tan
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Federico M Asch
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Eric J Velazquez
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Jean L Rouleau
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Kerry L Lee
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| | - Robert O Bonow
- From Westchester Medical Center, New York Medical College, Valhalla (J.A.P.); Duke Clinical Research Institute, Durham, NC (A.M.E., H.R.A.-K., D.B.M., K.L.L.); Northwestern University, Chicago (T.A.H., R.O.B.); Cedars Sinai Medical Center (D.S.B.) and the University of Southern California (G.M.P.), Los Angeles; Mayo Clinic, Rochester, MN (J.K.O.); the National Heart, Lung, and Blood Institute, Bethesda, MD (G.S.); Medical University of Lodz, Lodz (L.C.), and Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze (T.K.) - both in Poland; University Hospital Favaloro Foundation, Buenos Aires (L.E.F.); Medical University of Vienna, Vienna (G.M.); Instituto Dante Pazzanese de Cardiologia, São Paulo (P.S.F.); National Heart Center, Singapore (R.-S.T.); MedStar Washington Hospital Center, Washington, DC (F.M.A.); Yale University School of Medicine, New Haven, CT (E.J.V.); and Montreal Heart Institute, Montreal (J.L.R.)
| |
Collapse
|
26
|
Rochlani YM, Bhinder J, Pashkovetsky E, Yandrapalli S, Jolly G, Kai M, Cooper HA, Panza JA, Gass AL, Lanier GL. Primary Graft Dysfunction and Early Mortality in Heart Transplants from Drug Overdose Donors. J Card Fail 2019. [DOI: 10.1016/j.cardfail.2019.07.534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Gupta T, Kolte D, Khera S, Agarwal N, Villablanca PA, Goel K, Patel K, Aronow WS, Wiley J, Bortnick AE, Aronow HD, Abbott JD, Pyo RT, Panza JA, Menegus MA, Rihal CS, Fonarow GC, Garcia MJ, Bhatt DL. Contemporary Sex-Based Differences by Age in Presenting Characteristics, Use of an Early Invasive Strategy, and Inhospital Mortality in Patients With Non-ST-Segment-Elevation Myocardial Infarction in the United States. Circ Cardiovasc Interv 2019; 11:e005735. [PMID: 29311289 DOI: 10.1161/circinterventions.117.005735] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 12/07/2017] [Indexed: 12/13/2022]
Abstract
BACKGROUND Prior studies have reported higher inhospital mortality in women versus men with non-ST-segment-elevation myocardial infarction. Whether this is because of worse baseline risk profile compared with men or sex-based disparities in treatment is not completely understood. METHODS AND RESULTS We queried the 2003 to 2014 National Inpatient Sample databases to identify all hospitalizations in patients aged ≥18 years with the principal diagnosis of non-ST-segment-elevation myocardial infarction. Complex samples multivariable logistic regression models were used to examine sex differences in use of an early invasive strategy and inhospital mortality. Of 4 765 739 patients with non-ST-segment-elevation myocardial infarction, 2 026 285 (42.5%) were women. Women were on average 6 years older than men and had a higher comorbidity burden. Women were less likely to be treated with an early invasive strategy (29.4% versus 39.2%; adjusted odds ratio, 0.92; 95% confidence interval, 0.91-0.94). Women had higher crude inhospital mortality than men (4.7% versus 3.9%; unadjusted odds ratio, 1.22; 95% confidence interval, 1.20-1.25). After adjustment for age (adjusted odds ratio, 0.96; 95% confidence interval, 0.94-0.98) and additionally for comorbidities, other demographics, and hospital characteristics, women had 10% lower odds of inhospital mortality (adjusted odds ratio, 0.90; 95% confidence interval, 0.89-0.92). Further adjustment for differences in the use of an early invasive strategy did not change the association between female sex and lower risk-adjusted inhospital mortality. CONCLUSIONS Although women were less likely to be treated with an early invasive strategy compared with men, the lower use of an early invasive strategy was not responsible for the higher crude inhospital mortality in women, which could be entirely explained by older age and higher comorbidity burden.
Collapse
Affiliation(s)
- Tanush Gupta
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Dhaval Kolte
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Sahil Khera
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Nayan Agarwal
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Pedro A Villablanca
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Kashish Goel
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Kavisha Patel
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Wilbert S Aronow
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Jose Wiley
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Anna E Bortnick
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Herbert D Aronow
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - J Dawn Abbott
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Robert T Pyo
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Julio A Panza
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Mark A Menegus
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Charanjit S Rihal
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Gregg C Fonarow
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Mario J Garcia
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.)
| | - Deepak L Bhatt
- From the Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (T.G., J.W., A.E.B., R.T.P., M.A.M., M.J.G.); Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Division of Cardiology, Massachusetts General Hospital, Boston (S.K.); Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (N.A.); Division of Cardiology, New York University Langone Medical Center (P.A.V.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (K.G., C.S.R.); Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY (K.P.); Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla (W.S.A., J.A.P.); Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.); and Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.).
| |
Collapse
|
28
|
Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Meta-Analysis of Direct-Acting Oral Anticoagulants Compared With Warfarin in Patients >75 Years of Age. Am J Cardiol 2019; 123:2051-2057. [PMID: 30982541 DOI: 10.1016/j.amjcard.2019.02.060] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2018] [Revised: 02/19/2019] [Accepted: 02/22/2019] [Indexed: 11/15/2022]
Abstract
Older patients with atrial fibrillation (AF) are at higher risk of thromboembolic events and oral anticoagulant (OAC)-related bleeding complications. This meta-analysis evaluates the efficacy and safety of direct-acting OACs (DOACs) compared with warfarin in older patients with nonvalvular AF. PubMed, Embase, and Cochrane Central databases were searched for randomized controlled trials assessing the efficacy and safety of DOACs compared with warfarin in AF patients who were >75 years old. Treatment effects and relevant standard errors were calculated from the available data. These values were imputed in software R to perform meta-analysis through generic inverse variance method. Additionally, we performed a network meta-analysis to compare the relative efficacy and safety of each OAC. Five substudies of randomized controlled trials, comprising 28,135 older participants, were included in the analysis. DOACs as a group were found to have superior efficacy compared with warfarin in reducing stroke or systemic embolization (hazard ratio 0.76, 95% confidence intervals 0.67 to 0.86, p <0.01). The rate of major bleeding was similar, but intracranial hemorrhage was significantly lower in patients randomized to a DOAC (hazard ratio 0.48, 95% confidence intervals 0.34 to 0.67, p <0.01). Apixaban was the only DOAC that significantly reduced all 3 outcomes of systemic embolization, major bleeding, and intracranial hemorrhage compared with warfarin (by 29%, 36%, and 66%, respectively). In conclusion, DOACs were found to be safer and more effective than warfarin for the treatment of nonvalvular AF in older patients. Apixaban appears to provide the best combination of efficacy and safety in this population.
Collapse
Affiliation(s)
- Aaqib H Malik
- Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York.
| | - Srikanth Yandrapalli
- Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York
| | - Wilbert S Aronow
- Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York
| | - Julio A Panza
- Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York
| | - Howard A Cooper
- Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York
| |
Collapse
|
29
|
Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart 2019; 105:1432-1436. [PMID: 31203254 DOI: 10.1136/heartjnl-2019-314767] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Revised: 03/14/2019] [Accepted: 03/18/2019] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVE Current guidelines endorse the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). However, little is known about their safety and efficacy in valvular heart disease (VHD). Similarly, there is a paucity of data regarding NOACs use in patients with a bioprosthetic heart valve (BPHV). We, therefore, performed a network meta-analysis in the subgroups of VHD and meta-analysis in patients with a BPHV. METHODS PubMed, Cochrane and Embase were searched for randomised controlled trials. Summary effects were estimated by the random-effects model. The outcomes of interest were a stroke or systemic embolisation (SSE), myocardial infarction (MI), all-cause mortality, major adverse cardiac events, major bleeding and intracranial haemorrhage (ICH). RESULTS In patients with VHD, rivaroxaban was associated with more ICH and major bleeding than other NOACs, while edoxaban 30 mg was associated with least major bleeding. Data combining all NOACs showed a significant reduction in SSE, MI and ICH (0.70, [0.57 to 0.85; p<0.001]; 0.70 [0.50 to 0.99; p<0.002]; and 0.46 [0.24 to 0.86; p<0.01], respectively). Analysis of 280 patients with AF and a BPHV showed similar outcomes with NOACs and warfarin. CONCLUSIONS NOACs performed better than warfarin for a reduction in SSE, MI and ICH in patients with VHD. Individually NOACs performed similarly to each other except for an increased risk of ICH and major bleeding with rivaroxaban and a reduced risk of major bleeding with edoxaban 30 mg. In patients with a BPHV, results with NOACs seem similar to those with warfarin and this needs to be further explored in larger studies.
Collapse
Affiliation(s)
- Aaqib H Malik
- Department of Medicine, New York Medical College in Westchester Medical Center, Valhalla, New York, USA
| | | | - Wilbert S Aronow
- Department of Cardiology, New York Medical College, Valhalla, New York, USA
| | - Julio A Panza
- Department of Cardiology, New York Medical College, Valhalla, New York, USA
| | - Howard A Cooper
- Department of Cardiology, New York Medical College, Valhalla, New York, USA
| |
Collapse
|
30
|
|
31
|
Naidu SS, Panza JA. Hypertrophic Cardiomyopathy: Mastering the Multiple Facets of a Complex Disease. Cardiol Clin 2019; 37:ix-x. [DOI: 10.1016/j.ccl.2018.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Pellikka PA, She L, Holly TA, Lin G, Varadarajan P, Pai RG, Bonow RO, Pohost GM, Panza JA, Berman DS, Prior DL, Asch FM, Borges-Neto S, Grayburn P, Al-Khalidi HR, Miszalski-Jamka K, Desvigne-Nickens P, Lee KL, Velazquez EJ, Oh JK. Variability in Ejection Fraction Measured By Echocardiography, Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. JAMA Netw Open 2018; 1:e181456. [PMID: 30646130 PMCID: PMC6324278 DOI: 10.1001/jamanetworkopen.2018.1456] [Citation(s) in RCA: 123] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
IMPORTANCE Clinical decisions are frequently based on measurement of left ventricular ejection fraction (LVEF). Limited information exists regarding inconsistencies in LVEF measurements when determined by various imaging modalities and the potential impact of such variability. OBJECTIVE To determine the intermodality variability of LVEF measured by echocardiography, gated single-photon emission computed tomography (SPECT), and cardiovascular magnetic resonance (CMR) in patients with left ventricular dysfunction. DESIGN, SETTING, AND PARTICIPANTS International multicenter diagnostic study with LVEF imaging performed at 127 clinical sites in 26 countries from July 24, 2002, to May 5, 2007, and measured by core laboratories. Secondary study of clinical diagnostic measurements of LVEF in the Surgical Treatment for Ischemic Heart Failure (STICH), a randomized trial to identify the optimal treatment strategy for patients with LVEF of 35% or less and coronary artery disease. Data analysis was conducted from March 19, 2016, to May 29, 2018. MAIN OUTCOMES AND MEASURES At baseline, most patients had an echocardiogram and subsets of patients underwent SPECT and/or CMR. Left ventricular ejection fraction was measured by a core laboratory for each modality independent of the results of other modalities, and measurements were compared among imaging methods using correlation, Bland-Altman plots, and coverage probability methods. Association of LVEF by each method and death was assessed. RESULTS A total of 2032 patients (mean [SD] age, 60.9 [9.6] years; 1759 [86.6%] male) with baseline LVEF data were included. Correlation of LVEF between modalities was r = 0.601 (for biplane echocardiography and SPECT [n = 385]), r = 0.493 (for biplane echocardiography and CMR [n = 204]), and r = 0.660 (for CMR and SPECT [n = 134]). Bland-Altman plots showed only moderate agreement in LVEF measurements from all 3 core laboratories with no substantial overestimation or underestimation of LVEF by any modality. The percentage of observations that fell within a range of 5% ranged from 43% to 54% between different imaging modalities. CONCLUSIONS AND RELEVANCE In this international multicenter study of patients with coronary artery disease and reduced LVEF, there was substantial variation between modalities in LVEF determination by core laboratories. This variability should be considered in clinical management and trial design. TRIAL REGISTRATION Clinicaltrials.gov Identifier: NCT00023595.
Collapse
Affiliation(s)
| | - Lilin She
- Duke Clinical Research Institute, Durham, North Carolina
| | - Thomas A. Holly
- Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Grace Lin
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
| | - Padmini Varadarajan
- Department of Medicine, Loma Linda University, Loma Linda, California
- Department of Cardiology, Loma Linda University, Loma Linda, California
| | - Ramdas G. Pai
- Department of Medicine, Riverside School of Medicine, University of California, Riverside
- Department of Cardiology, Riverside School of Medicine, University of California, Riverside
| | - Robert O. Bonow
- Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Gerald M. Pohost
- Department of Medicine, Loma Linda University, Loma Linda, California
- Department of Cardiology, Loma Linda University, Loma Linda, California
| | - Julio A. Panza
- Westchester Medical Center, New York Medical College, Valhalla
| | | | - David L. Prior
- Department of Cardiology, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
- Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
| | - Federico M. Asch
- Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC
| | - Salvador Borges-Neto
- Division of Nuclear Medicine, Department of Radiology, Duke University School of Medicine, Durham, North Carolina
- Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Durham, North Carolina
| | - Paul Grayburn
- Cardiology Section, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas
| | - Hussein R. Al-Khalidi
- Duke Clinical Research Institute, Durham, North Carolina
- Department of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Durham, North Carolina
| | - Karol Miszalski-Jamka
- Division of Magnetic Resonance Imaging, Silesian Center for Heart Diseases, Zabrze, Poland
| | - Patrice Desvigne-Nickens
- Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Kerry L. Lee
- Duke Clinical Research Institute, Durham, North Carolina
- Department of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Durham, North Carolina
| | - Eric J. Velazquez
- Duke Clinical Research Institute, Durham, North Carolina
- Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Durham, North Carolina
| | - Jae K. Oh
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
| |
Collapse
|
33
|
Ojo AO, Gupta CA, Fuisz A, Solangi Z, Harikrishnan P, Cooper HA, Panza JA, Aronow WS. Myocarditis presenting as variant angina: a rare presentation. Arch Med Sci 2018; 14:1175-1179. [PMID: 30154903 PMCID: PMC6111353 DOI: 10.5114/aoms.2017.68931] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Accepted: 09/28/2016] [Indexed: 11/19/2022] Open
Affiliation(s)
- Amole O Ojo
- Department of Medicine, Division of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY, USA
| | - Chhaya A Gupta
- Department of Medicine, Division of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY, USA
| | - Anthon Fuisz
- Department of Medicine, Division of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY, USA
| | - Zeeshan Solangi
- Department of Medicine, Division of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY, USA
| | - Prakash Harikrishnan
- Department of Medicine, Division of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY, USA
| | - Howard A Cooper
- Department of Medicine, Division of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY, USA
| | - Julio A Panza
- Department of Medicine, Division of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY, USA
| | - Wilbert S Aronow
- Department of Medicine, Division of Cardiology, Westchester Medical Center/New York Medical College, Valhalla, NY, USA
| |
Collapse
|
34
|
Naidu SS, Jacobson J, Iwai S, Dutta T, Aronow WS, Poniros A, Malekan R, Spielvogel D, Panza JA. Interventional therapies for relief of obstruction in hypertrophic cardiomyopathy: discussion and proposed clinical algorithm. Hosp Pract (1995) 2018; 46:58-63. [PMID: 29490522 DOI: 10.1080/21548331.2018.1447738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Hypertrophic cardiomyopathy (HCM), a disease formerly thought rare in clinical practice, is now believed to affect as many as 1 in 300 individuals, regardless of race or gender. Rising awareness, coupled with advanced imaging and the development of dedicated HCM centers of excellence, has led to more patients coming to clinical presentation. While some are diagnosed at a young age, others are diagnosed in middle age or well into advanced age. Unfortunately, many such patients have progressed clinically to overt heart failure, or have some combination of advanced symptoms including dyspnea, angina, pre-syncope or syncope, palpitations, and edema. Anatomic subsets, including those with mid-ventricular obstruction or apical disease, with or without apical aneurysm, have also been seen in increasing frequency. Fortunately, both percutaneous and surgical invasive options are available across the spectrum of disease severity and anatomy, with outcomes continuing to improve as the techniques and experience evolve. Advances in both approaches allow targeted and individualized treatment of the majority of these patients. This review will focus on interventional approaches to relief of obstruction, and will provide a current clinical algorithm from our center for determining when an interventional approach may be recommended or optimal over a surgical approach, and vice versa.
Collapse
Affiliation(s)
- Srihari S Naidu
- a Division of Cardiology, Department of Medicine , Westchester Medical Center , Valhalla , NY , USA
| | - Jason Jacobson
- a Division of Cardiology, Department of Medicine , Westchester Medical Center , Valhalla , NY , USA
| | - Sei Iwai
- a Division of Cardiology, Department of Medicine , Westchester Medical Center , Valhalla , NY , USA
| | - Tanya Dutta
- a Division of Cardiology, Department of Medicine , Westchester Medical Center , Valhalla , NY , USA
| | - Wilbert S Aronow
- a Division of Cardiology, Department of Medicine , Westchester Medical Center , Valhalla , NY , USA
| | - Angelica Poniros
- a Division of Cardiology, Department of Medicine , Westchester Medical Center , Valhalla , NY , USA
| | - Ramin Malekan
- b Department of Cardiothoracic Surgery , Westchester Medical Center , Valhalla , NY , USA
| | - David Spielvogel
- b Department of Cardiothoracic Surgery , Westchester Medical Center , Valhalla , NY , USA
| | - Julio A Panza
- a Division of Cardiology, Department of Medicine , Westchester Medical Center , Valhalla , NY , USA
| |
Collapse
|
35
|
Gupta T, Patel K, Kolte D, Khera S, Villablanca PA, Aronow WS, Frishman WH, Cooper HA, Bortnick AE, Fonarow GC, Panza JA, Weisz G, Menegus MA, Garcia MJ, Bhatt DL. Relationship of Hospital Teaching Status with In-Hospital Outcomes for ST-Segment Elevation Myocardial Infarction. Am J Med 2018; 131:260-268.e1. [PMID: 29037939 DOI: 10.1016/j.amjmed.2017.09.047] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Revised: 09/10/2017] [Accepted: 09/11/2017] [Indexed: 11/25/2022]
Abstract
BACKGROUND Prior analyses have largely shown a survival advantage with admission to a teaching hospital for acute myocardial infarction. However, most prior studies report data on patients hospitalized over a decade ago. It is important to re-examine the association of hospital teaching status with outcomes of acute myocardial infarction in the current era. METHODS We queried the 2010 to 2014 National Inpatient Sample databases to identify all patients aged ≥18 years hospitalized with the principal diagnosis of ST-segment elevation myocardial infarction (STEMI). Multivariable logistic regression models were constructed to compare rates of reperfusion and in-hospital outcomes between patients admitted to teaching vs nonteaching hospitals. RESULTS Of 546,252 patients with STEMI, 273,990 (50.1%) were admitted to teaching hospitals. Compared with patients admitted to nonteaching hospitals, those at teaching hospitals were more likely to receive reperfusion therapy during the hospitalization (86.7% vs 81.5%; adjusted odds ratio [OR] 1.41; 95% confidence interval [CI], 1.39-1.44; P < .001) and had lower risk-adjusted in-hospital mortality (4.9% vs 6.9%; adjusted OR 0.84; 95% CI, 0.82-0.86; P < .001). After further adjustment for differences in use of in-hospital reperfusion therapy, the association of teaching hospital status with lower risk-adjusted in-hospital mortality was significantly attenuated but remained statistically significant (adjusted OR 0.97; 95% CI, 0.94-0.99; P = .02). CONCLUSIONS Patients admitted to teaching hospitals are more likely to receive reperfusion and have lower risk-adjusted in-hospital mortality after STEMI compared with those admitted to nonteaching hospitals. Our results suggest that hospital performance for STEMI continues to be better at teaching hospitals in the contemporary era.
Collapse
Affiliation(s)
- Tanush Gupta
- Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - Kavisha Patel
- Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - Dhaval Kolte
- Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, RI
| | - Sahil Khera
- Division of Cardiology, Massachusetts General Hospital, Boston
| | - Pedro A Villablanca
- Division of Cardiology, New York University Langone Medical Center, New York
| | - Wilbert S Aronow
- Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla
| | - William H Frishman
- Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla
| | - Howard A Cooper
- Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla
| | - Anna E Bortnick
- Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - Gregg C Fonarow
- Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles
| | - Julio A Panza
- Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla
| | - Giora Weisz
- Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - Mark A Menegus
- Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - Mario J Garcia
- Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - Deepak L Bhatt
- Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA.
| |
Collapse
|
36
|
Gupta T, Kalra A, Kolte D, Khera S, Villablanca PA, Goel K, Bortnick AE, Aronow WS, Panza JA, Kleiman NS, Abbott JD, Slovut DP, Taub CC, Fonarow GC, Reardon MJ, Rihal CS, Garcia MJ, Bhatt DL. Regional Variation in Utilization, In-hospital Mortality, and Health-Care Resource Use of Transcatheter Aortic Valve Implantation in the United States. Am J Cardiol 2017; 120:1869-1876. [PMID: 28865889 DOI: 10.1016/j.amjcard.2017.07.102] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Revised: 07/17/2017] [Accepted: 07/24/2017] [Indexed: 10/19/2022]
Abstract
We queried the National Inpatient Sample database from 2012 to 2014 to identify all patients aged ≥18 years undergoing transcatheter aortic valve implantation (TAVI) in the United States. Regional differences in TAVI utilization, in-hospital mortality, and health-care resource use were analyzed. Of 41,025 TAVI procedures in the United States between 2012 and 2014, 10,390 were performed in the Northeast, 9,090 in the Midwest, 14,095 in the South, and 7,450 in the West. Overall, the number of TAVI implants per million adults increased from 24.8 in 2012 to 63.2 in 2014. The utilization of TAVI increased during the study period in all 4 geographic regions, with the number of implants per million adults being highest in the Northeast, followed by the Midwest, South, and West, respectively. Overall in-hospital mortality was 4.2%. Compared with the Northeast, risk-adjusted in-hospital mortality was higher in the Midwest (adjusted odds ratio [aOR] 1.26 [1.07 to 1.48]) and the South (aOR 1.61 [1.40 to 1.85]) and similar in the West (aOR 1.00 [0.84 to 1.18]). Average length of stay was shorter in all other regions compared with the Northeast. Among patients surviving to discharge, disposition to a skilled nursing facility or home health care was most common in the Northeast, whereas home discharge was most common in the West. Average hospital costs were highest in the West. In conclusion, we observed significant regional differences in TAVI utilization, in-hospital mortality, and health-care resource use in the United States. The findings of our study may have important policy implications and should provide an impetus to understand the source of this regional variation.
Collapse
|
37
|
Kolte D, Sardar P, Khera S, Zeymer U, Thiele H, Hochadel M, Radovanovic D, Erne P, Hambraeus K, James S, Claessen BE, Henriques JP, Mylotte D, Garot P, Aronow WS, Owan T, Jain D, Panza JA, Frishman WH, Fonarow GC, Bhatt DL, Aronow HD, Abbott JD. Culprit Vessel–Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment–Elevation Myocardial Infarction. Circ Cardiovasc Interv 2017; 10:CIRCINTERVENTIONS.117.005582. [PMID: 29146672 DOI: 10.1161/circinterventions.117.005582] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Accepted: 09/21/2017] [Indexed: 11/16/2022]
Affiliation(s)
- Dhaval Kolte
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Partha Sardar
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Sahil Khera
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Uwe Zeymer
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Holger Thiele
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Matthias Hochadel
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Dragana Radovanovic
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Paul Erne
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Kristina Hambraeus
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Stefan James
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Bimmer E. Claessen
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Jose P.S. Henriques
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Darren Mylotte
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Philippe Garot
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Wilbert S. Aronow
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Theophilus Owan
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Diwakar Jain
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Julio A. Panza
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - William H. Frishman
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Gregg C. Fonarow
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Deepak L. Bhatt
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - Herbert D. Aronow
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| | - J. Dawn Abbott
- From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.); Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.); Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.); Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.); Department of Cardiology, University Heart
| |
Collapse
|
38
|
Katchi T, Cooper HA, Yandrapalli SS, Khera S, Fallon J, Spielvogel D, Aronow WS, Panza JA. Prosthetic Aortic Valve Endocarditis Without Evidence of Vegetation. J Heart Valve Dis 2017; 26:365-367. [PMID: 29092126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Despite significant technological advances, the diagnosis of infective endocarditis (IE) remains a major challenge, and the condition continues to be associated with significant morbidity and mortality. Valvular vegetations have long been the diagnostic and pathologic hallmarks of IE. However, IE can be diagnosed even in the absence of vegetations using the modified Duke criteria. Vegetation-negative endocarditis is rare, and to the present authors' knowledge no cases of septic emboli in the absence of valvular vegetations have been reported. Herein is reported a case of prosthetic aortic valve endocarditis associated with both clinical and radiologic evidence of septic emboli, but in the absence of vegetations on both repeated transesophageal echocardiography and pathologic evaluation. This case highlights the importance of maintaining a high clinical suspicion and a low threshold for the surgical replacement of a possibly infected valve, in patients that meet other clinical criteria for IE, even in the absence of detectable valvular vegetations.
Collapse
Affiliation(s)
- Tasleem Katchi
- Department of Internal Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Howard A Cooper
- Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA. Electronic correspondence:
| | - Srikanth S Yandrapalli
- Department of Internal Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Sahil Khera
- Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - John Fallon
- Department of Pathology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - David Spielvogel
- Department of Cardiothoracic Surgery, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Wilbert S Aronow
- Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| | - Julio A Panza
- Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
| |
Collapse
|
39
|
Gupta T, Kolte D, Khera S, Goel K, Aronow WS, Cooper HA, Jain D, Rihal CS, Fonarow GC, Panza JA, Bhatt DL. Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients. JAMA Cardiol 2017; 2:250-258. [PMID: 28097322 DOI: 10.1001/jamacardio.2016.5131] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 09/20/2023]
Abstract
IMPORTANCE Renal transplantation is associated with reduction in the risk for myocardial infarction (MI) in patients with chronic kidney disease requiring long-term dialysis (stage 5D CKD). Whether outcomes of MI differ among renal transplant recipients vs patients with stage 5D CKD or those without CKD has not been well examined. OBJECTIVES To compare in-hospital reperfusion rates and outcomes of ST-segment elevation MI (STEMI) in renal transplant recipients vs the stage 5D CKD group or the non-CKD group. DESIGN, SETTING, AND PARTICIPANTS The National Inpatient Sample database was queried to identify patients 18 years or older who were hospitalized with the principal diagnosis of STEMI. All hospitalizations for STEMI in the United States from January 1, 2003, to December 31, 2013, were included. Codes from International Classification of Diseases, Ninth Revision, Clinical Modification, were used to identify patients in the non-CKD, stage 5D CKD, or prior renal transplant groups. Data were analyzed from March to May 2016. MAIN OUTCOMES AND MEASURES In-hospital mortality. RESULTS From 2003 to 2013, 2 319 002 patients in the non-CKD group (34.7% women; 65.3% men; mean [SD] age, 64.2 [14.4] years), 30 072 patients in the stage 5D CKD group (45.0% women; 55.0% men; mean [SD] age, 66.9 [12.5] years), and 2980 patients in the renal transplant group (27.3% women; 72.7% men; mean [SD] age, 57.5 [11.1] years) were identified who were hospitalized with STEMI. Of these, 68.9% of the patients in the non-CKD group, 39.5% in the stage 5D CKD group, and 65.2% in the renal transplant group received in-hospital reperfusion for STEMI. The renal transplant group was more likely to receive reperfusion compared with the stage 5D CKD group (adjusted odds ratio [AOR], 1.83; 95% CI, 1.67-2.01; P < .001) but less likely compared with the non-CKD group (AOR, 0.75; 95% CI, 0.68-0.83; P < .001). Risk-adjusted in-hospital mortality among the renal transplant group with STEMI was markedly lower compared with the stage 5D CKD group (AOR, 0.37; 95% CI, 0.33-0.43; P < .001) but similar compared with the non-CKD group (AOR, 1.14; 95% CI, 0.99-1.31; P = .08). Among renal transplant recipients with STEMI, the use of reperfusion increased from 53.7% in the 2003-2004 interval to 81.4% in the 2011-2013 interval (AOR, 1.33; 95% CI, 1.25-1.43; P < .001 for trend), whereas risk-adjusted in-hospital mortality remained unchanged during the study period, from 8.9% in the 2003-2004 interval to 6.1% in the 2011-2013 interval (AOR, 0.94; 95% CI, 0.85-1.05; P = .27 for trend). CONCLUSIONS AND RELEVANCE In-hospital mortality rates in renal transplant recipients with STEMI are more favorable compared with those of patients with stage 5D CKD and approach those of the general population with STEMI.
Collapse
Affiliation(s)
- Tanush Gupta
- Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York2Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
| | - Dhaval Kolte
- Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, Rhode Island
| | - Sahil Khera
- Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York
| | - Kashish Goel
- Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
| | - Wilbert S Aronow
- Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York
| | - Howard A Cooper
- Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York
| | - Diwakar Jain
- Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York
| | - Charanjit S Rihal
- Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
| | - Gregg C Fonarow
- Division of Cardiology, Ronald Reagan-UCLA (University of California, Los Angeles) Medical Center
| | - Julio A Panza
- Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York
| | - Deepak L Bhatt
- Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
40
|
Naidu SS, Panza JA, Spielvogel D, Malekan R, Goldberg J, Aronow WS. Does relief of outflow tract obstruction in patients with hypertrophic cardiomyopathy improve long-term survival? Implications for lowering the threshold for surgical myectomy and alcohol septal ablation. Ann Transl Med 2017; 4:485. [PMID: 28149847 DOI: 10.21037/atm.2016.12.47] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Srihari S Naidu
- Division of Cardiology and the Division of Cardiothoracic Surgery, Heart and Vascular Institute, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Julio A Panza
- Division of Cardiology and the Division of Cardiothoracic Surgery, Heart and Vascular Institute, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - David Spielvogel
- Division of Cardiology and the Division of Cardiothoracic Surgery, Heart and Vascular Institute, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Ramin Malekan
- Division of Cardiology and the Division of Cardiothoracic Surgery, Heart and Vascular Institute, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Joshua Goldberg
- Division of Cardiology and the Division of Cardiothoracic Surgery, Heart and Vascular Institute, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Wilbert S Aronow
- Division of Cardiology and the Division of Cardiothoracic Surgery, Heart and Vascular Institute, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| |
Collapse
|
41
|
Garg A, Balasubramaniyam N, Lafaro R, Timmermans R, Aronow WS, Cooper HA, Panza JA. Contained Rupture of Sinus of Valsalva Aneurysm in a 64-Year-Old Man. Tex Heart Inst J 2016; 43:433-436. [PMID: 27777531 DOI: 10.14503/thij-15-5182] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We report a contained rupture of a right coronary sinus of Valsalva aneurysm, in which repair resulted in symptomatic improvement. Patients often present with symptoms secondary to rupture of the sinus of Valsalva aneurysm into one of the cardiac chambers, or secondary to the compression of adjacent structures. Whereas sinus of Valsalva aneurysms and their rupture are well reported in the literature, contained ruptures have been described only rarely. In those cases, symptoms often arose from compression of adjacent structures. Although transesophageal echocardiography is considered to be the diagnostic method of choice, cardiac magnetic resonance imaging and computed tomography can be equally helpful in establishing the diagnosis and delineating the lesion. Diagnosis and prompt repair in our 64-year-old patient resulted in the rapid resolution of his symptoms.
Collapse
|
42
|
Cardillo C, Mettimano M, Mores N, Koh KK, Campia U, Panza JA. Plasma levels of cell adhesion molecules during hyperinsulinemia and modulation of vasoactive mediators. Vasc Med 2016; 9:185-8. [PMID: 15675182 DOI: 10.1191/1358863x04vm546oa] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Endothelial expression of cell adhesion molecules (CAMs) plays an important role in atherosclerosis. Atherosclerosis is increased in hyperinsulinemic states, but whether insulin per se is proatherogenic remains unclear. To investigate the effects of hyperinsulinemia on CAM expression, plasma levels of ICAM-1, VCAM-1 and E-selectin were measured before and after forearm infusion of insulin in healthy subjects. Insulin administration for 2 h resulted in signifi-cant hyperinsulinemia, whereas no significant change was observed in soluble CAMs (all p > 0.05). Because insulin stimulates endothelial release of both endothelin-1 (ET-1) and nitric oxide (NO), which may modulate the expression of CAMs, we also investigated the response of CAMs to ET-1 receptor blockade, alone and in combination with NO synthesis inhibition. ET-1 receptor blockade during hyperinsulinemia resulted in a vasodilator response, but did not affect soluble CAMs (all p > 0.05). Superimposition of NO inhibition by l-NMMA reversed the vasodilator effect of ET-1 blockade, without affecting soluble CAMs (all p > 0.05). In conclusion, acute hyperinsulinemia, alone or during ET-1 and NO pathway blockade, does not affect soluble CAMs. These results do not support a direct effect of insulin on endothelial cells to affect leukocyte adhesiveness to the vascular wall.
Collapse
|
43
|
Gupta T, Kolte D, Mohananey D, Khera S, Goel K, Mondal P, Aronow WS, Jain D, Cooper HA, Iwai S, Frishman WH, Bhatt DL, Fonarow GC, Panza JA. Relation of Obesity to Survival After In-Hospital Cardiac Arrest. Am J Cardiol 2016; 118:662-7. [PMID: 27381664 DOI: 10.1016/j.amjcard.2016.06.019] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Revised: 06/03/2016] [Accepted: 06/03/2016] [Indexed: 12/30/2022]
Abstract
Previous studies have shown that obesity is paradoxically associated with improved outcomes in many cardiovascular (CV) disease states; however, whether obesity affects survival after in-hospital cardiac arrest (IHCA) has not been well examined. We queried the 2003 to 2011 Nationwide Inpatient Sample databases to identify all patients aged ≥18 years who underwent cardiopulmonary resuscitation for IHCA. Obese patients were identified using the co-morbidity variable for obesity, as defined in Nationwide Inpatient Sample databases. Survival to hospital discharge was compared between obese and nonobese patients using multivariate regression models. Of 836,289 patients with IHCA, 67,216 (8.0%) were obese. Obese patients were younger and more likely to be women compared with nonobese patients. Despite being younger, obese patients had significantly higher prevalence of most CV co-morbidities such as dyslipidemia, coronary artery disease, previous myocardial infarction, heart failure, diabetes mellitus, hypertension, peripheral vascular disease, and chronic renal failure (p <0.001 for all). Obese patients were more likely to have ventricular tachycardia or ventricular fibrillation as the initial cardiac arrest rhythm (22.3% vs 20.9%; p <0.001). After multivariate risk adjustment, obese patients had improved survival to hospital discharge compared with nonobese patients (31.4% vs 24.1%; unadjusted odds ratio 1.44, 95% CI 1.42 to 1.47, p <0.001; adjusted odds ratio 1.15, 95% CI 1.13 to 1.17, p <0.001). Similar results were seen in patients with CV or non-CV conditions as the primary diagnosis and in those with ventricular tachycardia/ventricular fibrillation or pulseless electrical activity/asystole as the cardiac arrest rhythm. In conclusion, this large retrospective analysis of a nationwide cohort of patients with IHCA demonstrated higher risk-adjusted odds of survival in obese patients, consistent with an "obesity paradox."
Collapse
Affiliation(s)
- Tanush Gupta
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - Dhaval Kolte
- Division of Cardiology, Warren Alpert Medical School, Brown University, Providence, Rhode Island
| | - Divyanshu Mohananey
- Department of Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois
| | - Sahil Khera
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - Kashish Goel
- Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
| | - Pratik Mondal
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - Wilbert S Aronow
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York.
| | - Diwakar Jain
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - Howard A Cooper
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - Sei Iwai
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - William H Frishman
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - Deepak L Bhatt
- Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, Massachusetts
| | - Gregg C Fonarow
- Division of Cardiology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
| | - Julio A Panza
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| |
Collapse
|
44
|
Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, Velazquez EJ. Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation 2016; 134:1314-1324. [PMID: 27573034 DOI: 10.1161/circulationaha.116.024800] [Citation(s) in RCA: 106] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Accepted: 08/14/2016] [Indexed: 11/16/2022]
Abstract
BACKGROUND Advancing age is associated with a greater prevalence of coronary artery disease in heart failure with reduced ejection fraction and with a higher risk of complications after coronary artery bypass grafting (CABG). Whether the efficacy of CABG compared with medical therapy (MED) in patients with heart failure caused by ischemic cardiomyopathy is the same in patients of different ages is unknown. METHODS A total of 1212 patients (median follow-up, 9.8 years) with ejection fraction ≤35% and coronary disease amenable to CABG were randomized to CABG or MED in the STICH trial (Surgical Treatment for Ischemic Heart Failure). RESULTS Mean age at trial entry was 60 years; 12% were women; 36% were nonwhite; and the baseline ejection fraction was 28%. For the present analyses, patients were categorized by age quartiles: quartile 1, ≤54 years; quartile, 2 >54 and ≤60 years; quartile 3, >60 and ≤67 years; and quartile 4, >67 years. Older versus younger patients had more comorbidities. All-cause mortality was higher in older compared with younger patients assigned to MED (79% versus 60% for quartiles 4 and 1, respectively; log-rank P=0.005) and CABG (68% versus 48% for quartiles 4 and 1, respectively; log-rank P<0.001). In contrast, cardiovascular mortality was not statistically significantly different across the spectrum of age in the MED group (53% versus 49% for quartiles 4 and 1, respectively; log-rank P=0.388) or CABG group (39% versus 35% for quartiles 4 and 1, respectively; log-rank P=0.103). Cardiovascular deaths accounted for a greater proportion of deaths in the youngest versus oldest quartile (79% versus 62%). The effect of CABG versus MED on all-cause mortality tended to diminish with increasing age (Pinteraction=0.062), whereas the benefit of CABG on cardiovascular mortality was consistent over all ages (Pinteraction=0.307). There was a greater reduction in all-cause mortality or cardiovascular hospitalization with CABG versus MED in younger compared with older patients (Pinteraction=0.004). In the CABG group, cardiopulmonary bypass time or days in intensive care did not differ for older versus younger patients. CONCLUSIONS CABG added to MED has a more substantial benefit on all-cause mortality and the combination of all-cause mortality and cardiovascular hospitalization in younger compared with older patients. CABG added to MED has a consistent beneficial effect on cardiovascular mortality regardless of age. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.
Collapse
Affiliation(s)
- Mark C Petrie
- BHF GCRC, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Pardeep S Jhund
- BHF GCRC, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Lilin She
- Duke Clinical Research Institute and Departments of Biostatistics and Bioinformatics (KLL) and Medicine (EJV), Duke University School of Medicine, Durham, North Carolina, USA
| | - Christopher Adlbrecht
- Department of Medicine II, Division of Cardiology, Medical University of Vienna and 4 Medical Department, Hietzing Hospital, Vienna, Austria
| | - Torsten Doenst
- Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller University of Jena, Germany
| | - Julio A Panza
- Westchester Medical Center and New York Medical College, Valhalla, New York, USA
| | | | - Kerry L Lee
- Duke Clinical Research Institute and Departments of Biostatistics and Bioinformatics (KLL) and Medicine (EJV), Duke University School of Medicine, Durham, North Carolina, USA
| | - Jean L Rouleau
- University of Montreal, Montreal Heart Institute, Montreal, Canada
| | - David L Prior
- Department of Cardiology, St. Vincent's Hospital, University of Melbourne, Australia
| | - Imtiaz S Ali
- Libin Cardiovascular Institute of Alberta, University of Calgary, Canada
| | - Jyotsna Maddury
- Department of Cardiology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India
| | - Krzysztof S Golba
- Department of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, Poland
| | - Harvey D White
- Auckland City Hospital Greenlane Cardiovascular Services, Auckland, New Zealand
| | | | | | - Alexander Romanov
- Arrhythmia Department and Electrophysiology Laboratory, State Research Institute of Circulation Pathology, Novosibirsk, Russia
| | - Alan B Miller
- Department of Cardiology, University of Florida, Jacksonville, USA
| | - Eric J Velazquez
- Duke Clinical Research Institute and Departments of Biostatistics and Bioinformatics (KLL) and Medicine (EJV), Duke University School of Medicine, Durham, North Carolina, USA
| | | |
Collapse
|
45
|
Krepp JM, Hebsur S, Panza JA, Cooper HA, Asch FM. A shift in coronary care unit patient population: Ten year experience from an urban tertiary care center. ACTA ACUST UNITED AC 2016; 17:83-84. [DOI: 10.1080/17482941.2016.1203160] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Joseph M. Krepp
- MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC, USA
| | - Shrinivas Hebsur
- University of California San Diego, Division of Cardiac Electrophysiology, San Diego, CA, USA
| | - Julio A. Panza
- Division of Cardiology, Westchester Medical Center, Valhalla, NY, USA
| | - Howard A. Cooper
- Division of Cardiology, Westchester Medical Center, Valhalla, NY, USA
| | - Federico M. Asch
- MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC, USA
| |
Collapse
|
46
|
Paudel R, Beridze N, Aronow WS, Ahn C, Sanaani A, Agarwal P, Farell K, Jain D, Timmermans R, Cooper HA, Panza JA. Association of chest pain versus dyspnea as presenting symptom for coronary angiography with demographics, coronary anatomy, and 2-year mortality. Arch Med Sci 2016; 12:742-6. [PMID: 27478454 PMCID: PMC4947621 DOI: 10.5114/aoms.2016.60959] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Accepted: 02/04/2015] [Indexed: 01/21/2023] Open
Abstract
INTRODUCTION The association of chest pain versus dyspnea with demographics, coronary angiographic findings, and outcomes of patients undergoing coronary angiography is unknown. MATERIAL AND METHODS We studied 1,053 patients who had coronary angiography to investigate the association of chest pain versus dyspnea with demographics, coronary angiographic findings, and outcomes. RESULTS Of 1,053 patients, 654 (62%) had chest pain, 229 (22%) had dyspnea, and 117 (11%) had chest pain and dyspnea. Patients with dyspnea were older (p < 0.0001) and had higher serum creatinine (p = 0.0011), lower left ventricular ejection fraction (LVEF) (p < 0.0001), more cardiogenic shock (p = 0.0004), less obstructive coronary artery disease (CAD) (p < 0.0001), less percutaneous coronary intervention (p < 0.0001), and similar 2-year mortality. Stepwise Cox regression analysis showed no significant difference in mortality between chest pain and dyspnea. Significant risk factors for time to death were age (hazard ratio (HR) = 1.07, p < 0.0001), serum creatinine (HR = 1.5, p < 0.0001), body mass index (HR = 0.93, p = 0.005), and obstructive CAD graft (HR = 3.2, p = 0.011). CONCLUSIONS Patients undergoing coronary angiography presenting with dyspnea were older and had higher serum creatinine, lower LVEF, more frequent cardiogenic shock, less obstructive CAD, and less percutaneous coronary intervention compared to patients presenting with chest pain but similar 2-year mortality.
Collapse
Affiliation(s)
- Rajiv Paudel
- Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Natalia Beridze
- Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Wilbert S. Aronow
- Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Chul Ahn
- Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Abdallah Sanaani
- Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Pallak Agarwal
- Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Kim Farell
- Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Diwakar Jain
- Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Robert Timmermans
- Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Howard A. Cooper
- Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| | - Julio A Panza
- Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
| |
Collapse
|
47
|
Goyal A, Gupta T, Aronow WS, Panza JA, Cooper HA. Making the Case for Universal Treatment of Hypercholesterolemia. Am J Cardiol 2016; 118:303-4. [PMID: 27236257 DOI: 10.1016/j.amjcard.2016.04.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2016] [Revised: 04/20/2016] [Accepted: 04/20/2016] [Indexed: 01/23/2023]
Affiliation(s)
- Abhishek Goyal
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - Tanush Gupta
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - Wilbert S Aronow
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - Julio A Panza
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York
| | - Howard A Cooper
- Division of Cardiology, Department of Medicine, New York Medical College, Valhalla, New York.
| |
Collapse
|
48
|
Gupta T, Kolte D, Khera S, Harikrishnan P, Mujib M, Aronow WS, Jain D, Ahmed A, Cooper HA, Frishman WH, Bhatt DL, Fonarow GC, Panza JA. Smoker's Paradox in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Am Heart Assoc 2016; 5:JAHA.116.003370. [PMID: 27107131 PMCID: PMC4843594 DOI: 10.1161/jaha.116.003370] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Prior studies have found that smokers undergoing thrombolytic therapy for ST-segment elevation myocardial infarction have lower in-hospital mortality than nonsmokers, a phenomenon called the "smoker's paradox." Evidence, however, has been conflicting regarding whether this paradoxical association persists in the era of primary percutaneous coronary intervention. METHODS AND RESULTS We used the 2003-2012 National Inpatient Sample databases to identify all patients aged ≥18 years who underwent primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Multivariable logistic regression was used to compare in-hospital mortality between smokers (current and former) and nonsmokers. Of the 985 174 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, 438 954 (44.6%) were smokers. Smokers were younger, were more often men, and were less likely to have traditional vascular risk factors than nonsmokers. Smokers had lower observed in-hospital mortality compared with nonsmokers (2.0% versus 5.9%; unadjusted odds ratio 0.32, 95% CI 0.31-0.33, P<0.001). Although the association between smoking and lower in-hospital mortality was partly attenuated after baseline risk adjustment, a significant residual association remained (adjusted odds ratio 0.60, 95% CI 0.58-0.62, P<0.001). This association largely persisted in age-stratified analyses. Smoking status was also associated with shorter average length of stay (3.5 versus 4.5 days, P<0.001) and lower incidence of postprocedure hemorrhage (4.2% versus 6.1%; adjusted odds ratio 0.81, 95% CI 0.80-0.83, P<0.001) and in-hospital cardiac arrest (1.3% versus 2.1%; adjusted OR 0.78, 95% CI 0.76-0.81, P<0.001). CONCLUSIONS In this nationwide cohort of patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction, we observed significantly lower risk-adjusted in-hospital mortality in smokers, suggesting that the smoker's paradox also applies to ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Collapse
Affiliation(s)
| | - Dhaval Kolte
- Brown University/Rhode Island Hospital, Providence, RI
| | | | | | | | | | | | - Ali Ahmed
- Veterans Affairs Medical Center, Washington, DC
| | | | | | - Deepak L Bhatt
- Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA
| | - Gregg C Fonarow
- David Geffen School of Medicine, University of California at Los Angeles, CA
| | | |
Collapse
|
49
|
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-Nickens P, Sopko G, Rouleau JL. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 2016; 374:1511-20. [PMID: 27040723 PMCID: PMC4938005 DOI: 10.1056/nejmoa1602001] [Citation(s) in RCA: 622] [Impact Index Per Article: 77.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND The survival benefit of a strategy of coronary-artery bypass grafting (CABG) added to guideline-directed medical therapy, as compared with medical therapy alone, in patients with coronary artery disease, heart failure, and severe left ventricular systolic dysfunction remains unclear. METHODS From July 2002 to May 2007, a total of 1212 patients with an ejection fraction of 35% or less and coronary artery disease amenable to CABG were randomly assigned to undergo CABG plus medical therapy (CABG group, 610 patients) or medical therapy alone (medical-therapy group, 602 patients). The primary outcome was death from any cause. Major secondary outcomes included death from cardiovascular causes and death from any cause or hospitalization for cardiovascular causes. The median duration of follow-up, including the current extended-follow-up study, was 9.8 years. RESULTS A primary outcome event occurred in 359 patients (58.9%) in the CABG group and in 398 patients (66.1%) in the medical-therapy group (hazard ratio with CABG vs. medical therapy, 0.84; 95% confidence interval [CI], 0.73 to 0.97; P=0.02 by log-rank test). A total of 247 patients (40.5%) in the CABG group and 297 patients (49.3%) in the medical-therapy group died from cardiovascular causes (hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006 by log-rank test). Death from any cause or hospitalization for cardiovascular causes occurred in 467 patients (76.6%) in the CABG group and in 524 patients (87.0%) in the medical-therapy group (hazard ratio, 0.72; 95% CI, 0.64 to 0.82; P<0.001 by log-rank test). CONCLUSIONS In a cohort of patients with ischemic cardiomyopathy, the rates of death from any cause, death from cardiovascular causes, and death from any cause or hospitalization for cardiovascular causes were significantly lower over 10 years among patients who underwent CABG in addition to receiving medical therapy than among those who received medical therapy alone. (Funded by the National Institutes of Health; STICH [and STICHES] ClinicalTrials.gov number, NCT00023595.).
Collapse
Affiliation(s)
- Eric J Velazquez
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Kerry L Lee
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Robert H Jones
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Hussein R Al-Khalidi
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - James A Hill
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Julio A Panza
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Robert E Michler
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Robert O Bonow
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Torsten Doenst
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Mark C Petrie
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Jae K Oh
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Lilin She
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Vanessa L Moore
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Patrice Desvigne-Nickens
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - George Sopko
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| | - Jean L Rouleau
- From the Division of Cardiology (E.J.V.), Departments of Biostatistics and Bioinformatics (K.L.L., H.R.A.-K.) and Surgery (R.H.J.), and Duke Clinical Research Institute (L.S., V.L.M.), Duke University Medical Center, Durham, NC; the University of Florida, Gainesville (J.A.H.); Westchester Medical Center and New York Medical College, Valhalla (J.A.P.), and Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York (R.E.M.); Northwestern University Feinberg School of Medicine, Chicago (R.O.B.); the Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University of Jena, Jena, Germany (T.D.); Glasgow University and Golden Jubilee National Hospital, Glasgow, United Kingdom (M.C.P.); Mayo Clinic, Rochester, MN (J.K.O.); the Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., G.S.); and University of Montreal, Montreal Heart Institute, Montreal (J.L.R.)
| |
Collapse
|
50
|
Agarwal S, Sud K, Khera S, Kolte D, Fonarow GC, Panza JA, Menon V. Trends in the Burden of Adult Congenital Heart Disease in US Emergency Departments. Clin Cardiol 2016; 39:391-8. [PMID: 27079279 DOI: 10.1002/clc.22541] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Revised: 02/29/2016] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND We assessed trends in incidence, in-hospital mortality, and admission among patients with adult congenital heart disease (ACHD) presenting to the emergency department (ED) from 2006 to 2012. HYPOTHESIS There is a considerable burden of ACHD in the US EDs. METHODS We used the 2006-2012 US Nationwide Emergency Department Sample. All ED visits with ACHD were identified using standard International Classification of Diseases, Ninth Edition, Clinical Modification codes. RESULTS The number of patients presenting to the ED with simple (40.6%) as well as complex (37.6%) ACHD across 2006-2012 increased significantly. Also, there was a considerable increase in prevalence of traditional cardiovascular risk factors among ACHD patients, including hypertension, diabetes, smoking, obesity, and chronic kidney disease. Besides miscellaneous noncardiovascular conditions, nonspecific chest pain (15.9%) and respiratory disorders (15.0%) were the most common reasons for ED visits among patients with simple and complex ACHD, respectively. Although there was a trend toward decrease in admissions across 2006-2012 (Ptrend < 0.001), the proportion of patients with ACHD presenting to ED requiring admission remained substantial (63.4%). Finally, there was significant variation in admission trends across different geographic locations, hospital types, insurance status, and ED volume among ACHD patients presenting to the ED. CONCLUSIONS There has been a progressive increase in number of ED visits among ACHD patients across 2006-2012 in the United States. Moreover, the cardiovascular risk-factor profile of ACHD patients has changed, adding to complexity in management. Current health care delivery to ACHD patients also shows significant geographical, hospital-based, and insurance status-based disparities.
Collapse
Affiliation(s)
- Shikhar Agarwal
- Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Ohio
| | - Karan Sud
- Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Ohio
| | - Sahil Khera
- Department of Cardiovascular Medicine, New York Medical College, Valhalla, New York
| | - Dhaval Kolte
- Department of Cardiovascular Medicine, Brown University, Providence, Rhode Island
| | - Gregg C Fonarow
- Department of Cardiovascular Medicine, University of California, Los Angeles, California
| | - Julio A Panza
- Department of Cardiovascular Medicine, New York Medical College, Valhalla, New York
| | - Venu Menon
- Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Ohio
| |
Collapse
|